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Abstract 
 
The gene PTPN11 was identified in the early 1990s, and encodes the non-
transmembrane protein tyrosine phosphatase SHP2. SHP2 is expressed ubiquitously in 
cells, and plays an important role in cancer. Unlike most phosphatases, SHP2 positively 
regulates several signaling pathways including the Ras/MAPK and Src signaling 
pathways and acts as a proto-oncogene. SHP2 is also a cancer essential gene in 
certain types of carcinomas, and promotes growth, survival, and epithelial to 
mesenchymal transformation. Gain of function (GOF) SHP2 mutations are known 
leukemic oncogenes, and have been identified to a smaller extent in solid tumors as 
well. Currently, the roles of SHP2 in lung carcinoma are not fully understood. While 
GOF SHP2 mutations have been detected in lung cancer, their contributions to cellular 
transformation had not been established. In addition, SHP2 is known to promote EGF 
growth factor receptor (EGFR) signaling. Since GOF EGFR mutations induce 
transformation of lung epithelial cells, it is possible that SHP2 plays a role in promoting 
GOF EGFR mutant driven tumorigenesis. The objective of this dissertation is to 
determine whether SHP2 can act as an oncogene in lung epithelial cells and whether 
SHP2 inhibition can affect GOF EGFR mutant induced lung cancer. To achieve these 
aims, we generated two novel doxycycline (Dox) inducible transgenic mouse models 
which express either the GOF SHP2E76K leukemic oncogene or the dominant negative 
SHP2CSDA mutant under the control of the Clara cell secretory protein (CCSP) promoter 
to regulate transgene expression to type II pneumocytes. 
 x 
To determine whether SHP2 plays a role in promoting GOF EGFR mutant signaling, 
we started by disrupting SHP2 function in vitro. Two non small lung cancer cell lines 
were used for this project: HCC827 carries the LREA deletion in exon 19, and H1975 
co-expresses the EGFRL858R point mutation and the EGFRT790M gatekeeper mutation. 
After SHP2 PTP inhibition or knock-down by shRNA and siRNA, both cell lines exhibited 
decreased cell proliferation and reduced levels of pErk1/2 and c-Myc. Based on these 
results, we acquired a transgenic mouse line which expresses the EGFRL858R mutant 
under the control of the tet-O promoter and generated bitransgenic CCSP-rtTA/tetO-
EGFRL858R and tritransgenic CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice to study 
the effects of the dominant negative SHP2CDSA mutant on EGFRL858R mediated 
carcinogenesis in vivo. After 4, 6, and 8 weeks of Dox induction, pErk1/2 and pSrc 
levels were increased in the lungs of bitransgenic mice compared to wild type controls. 
Both kinases were suppressed by SHP2CSDA expression in tritransgenic mice. In 
addition, SHP2CSDA expression delayed tumor onset and prevented progression to a 
more aggressive phenotype. Tritransgenic mice also developed a smaller tumor burden 
compared to bitransgenic animals. These results suggest that SHP2 is critical for GOF 
EGFR mutant mediated lung tumorigenesis and describe a new role of SHP2 as a 
potential therapeutic target for the development of novel NSCLC drugs. 
Once we generated our CCSP-rtTA/tetO-SHP2E76K transgenic mouse model, we 
administered Dox for one month and found that SHP2E76K expression upregulates 
pErk1/2, pSrc, pGab1, c-Myc and Mdm2 levels in the lungs of bitransgenic mice 
compared to controls. After six to nine months of Dox induction, SHP2E76K expression 
caused formation of lung adenomas and adenocarcinoma. We then took advantage of 
 xi 
the reversible feature of our mouse model to test whether lung tumors are dependent on 
sustained SHP2E76K expression for survival. MRI analysis of lung adenocarcinomas 
showed full regression of the lung tumors after Dox withdrawal. Histological evaluation 
of lung tissues revealed residual hyperplastic lesions as well as evidence of necrosis, 
while biochemical analysis showed that pGab1, pErk1/2, pSrc and c-Myc returned to 
basal levels. These results demonstrate that sustained SHP2E76K expression is required 
for lung tumor maintenance. Moreover, this data describe a novel function of SHP2E76K 
as an oncogene in lung carcinoma. 
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Chapter 1: Introduction 
 
1.1 Protein tyrosine phosphatases and protein tyrosine kinases 
Tyrosine phosphorylation is an essential step to induce cell signaling and was first 
reported in 1978 with the discovery of the Src tyrosine kinase [1, 2]. Extensive research 
has identified a multitude of protein tyrosine kinases (PTKs) and elucidated their roles in 
normal cellular function and cancer. Since for every action, there must be an equal and 
opposite reaction, the concept of a protein tyrosine phosphatase (PTP) which 
dephosphorylates tyrosine sites (Y) phosphorylated by PTKs was proposed. This 
hypothesis was confirmed a decade after the discovery of PTKs with the cloning of the 
protein tyrosine phosphatase PTP1B [3, 4]. Since then, the human “PTPome” has been 
extensively characterized with the identification of 107 PTPs grouped into four families. 
The majority of PTPs are included in the class I cysteine based group, and include the 
classical receptor PTPs, the non receptor PTPs and the dual specificity PTPs [5]. Class 
II includes the low molecular weight PTP and class III contains 3 Cdc25 proteins. Both 
class II and III are cysteine based. The fourth class includes Asp based PTPs [5].  
The common assumption at the time was that since PTPs perform the reverse 
function of PTKs, they should play a negative regulatory role in cell signaling and 
cancer. This idea was reinforced by the discovery and characterization of PTPs such as 
PTEN, DEP1, and TCPTP which decrease or terminate cell signaling and block 
activation of downstream targets of receptor tyrosine kinases (RTKs) [6-9]. Moreover, 
  
 
 
2 
these PTPs are often inactivated or lost through mutation, which potentiates cellular 
transformation leading to cancer development [10, 11]. These studies cemented the role 
of PTPs as negative regulators of cell signaling.  
Further research revealed that tyrosine phosphorylation by RTK does not always 
activate the target protein [12]. Indeed, multiple proteins are negatively regulated by 
tyrosine phosphorylation, which would indicate that dephosphorylation by a PTP would 
have a positive effect on cellular signaling [13-16]. This hypothesis was confirmed in 
2003 with the identification of GOF SHP2 mutations in patients afflicted with juvenile 
myelomonocytic leukemia [17]. In this disease, SHP2 acts as a proto-oncogene and 
drives leukemogenesis [18, 19]. Following this discovery, additional PTPs were found to 
act as proto-oncogenes, including RPTPα, PTPH1, and more [5, 20, 21]. These PTPs 
promote cell signaling, cellular transformation, survival, proliferation, and invasion [5]. 
Taken together these studies describe complex and opposing roles for the members of 
the PTPome in normal cellular function, development and cancer. PTPs are an 
important component of signal transduction, and should not be solely considered 
erasers of PTKs function. 
 
1.2 Discovery of the protein tyrosine phosphatase SHP2  
The gene PTPN11 was discovered in the early 1990s, and encodes the non-
transmembrane protein tyrosine phosphatase Src homology 2 domain tyrosine 
phosphatase (SHP2), previously called Syp, PTP1D, SH-PTP2, or PTP2C [22-25]. 
SHP2 contains a C-terminal tail with two tyrosyl phosphorylation sites (Y542 and Y580), 
a central PTP catalytic domain, and two N-terminal Src homology 2 (SH2) binding 
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domains (N-SH2 and C-SH2) (Fig. 1). SHP2 is regulated by an auto-inhibitory 
mechanism. In its inactive conformation, the N-SH2 binding domain folds over the PTP 
domain and restricts substrate access to the catalytic site (Fig. 1). Upon growth factor or 
cytokine stimulation, the SH2 binding domains bind to phosphorylated tyrosine sites on 
growth factor receptors or docking proteins causing SHP2 to unfold, exposing the PTP 
catalytic domain [26]. SHP2 is expressed ubiquitously, and plays an important role in 
development, normal cellular function, and cancer [27, 28]. Unlike most phosphatases, 
SHP2 positively regulates cell signaling and acts as a proto-oncogene [29].  
 
Figure 1. Crystal structure of SHP2. The crystal structure of un-liganded SHP2 was 
resolved in 1998 by the Shoelson group [30]. This structure is missing the c-terminal tail 
but otherwise contains the C-SH2 binding domain (yellow), the N-SH2 binding domain 
(red) and the PTP catalytic domain (green). The structure is in its inactive conformation, 
whereas the N-SH2 binding domain folds over the PTP domain and blocks substrate 
access to the catalytic cleft (magenta). 
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1.3 SHP2 is a positive regulator of cell signaling 
SHP2 is activated by several growth factor receptors including the platelet derived 
growth factor receptor (PDGFR), the epidermal growth factor receptor (EGFR), the 
fibroblast growth factor receptor (FGFR), and the insulin-like growth factor 1 receptor 
(IGF-1R) [31, 32]. As a result, SHP2 is involved in multiple cell signaling pathways and 
performs different roles depending on the activating growth factor receptor, though the 
main function of SHP2 is to promote the Ras/MAPK and Src signaling pathways through 
multiple incompletely defined mechanisms. 
 
1.3.1 The role of SHP2 in the Ras/MAPK signaling pathway 
An important mechanism for the promotion of Ras/MAPK signaling by SHP2 is its 
association with the docking protein Grb2 associated binder protein 1 (Gab1) [33, 34]. 
Phosphorylation of Gab1 on its SHP2 binding sites (Y627, Y659) by growth factor 
receptors recruits SHP2 to the cell membrane and relieves the auto-inhibitory 
mechanism, exposing the PTP catalytic domain (Fig. 2) [35]. Once activated, SHP2 
positively regulates Ras/MAPK signaling through both direct and indirect approaches. 
For example, PDGFR binds SHP2 which in turn directly recruits the growth factor 
receptor bound protein 2 (Grb2)/Son of Sevenless (SOS) complex to the cell membrane 
(Fig. 2) [31, 36]. SOS is a guanine nucleotide exchange factor that catalyzes the 
conversion of inactive GDP-bound Ras to active GTP-bound Ras, leading to activation 
of the Ras/MAPK signaling chain [37].  
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SHP2 can also indirectly prolong Ras/MAPK activity by interfering with the negative 
regulators of this signaling pathway such as p120RasGAP and the Sprouty-related, 
EVH1 domain-containing protein (SPRED) and Sprouty protein families. The 
p120RasGAP protein catalyzes hydrolyzation of the GTP-bound Ras to the inactive 
GDP-bound state [38]. To perform this function, p120RasGAP must bind to specific 
tyrosine sites on growth factor receptors or scaffolding protein such as Gab1. SHP2 
dephosphorylates these sites, which disrupts p120RasGAP function by blocking its 
recruitment to the cell membrane (Fig. 2) [36]. Sprouty is another negative regulator of 
Ras. This protein functions by binding Grb2 and sequestering the Grb2/SOS complex in 
the cytoplasm to prevent SOS mediated Ras activation [39]. SHP2 dephosphorylates 
the Grb2 binding site on Sprouty, enabling relocation of the Grb2/SOS complex to the 
cell membrane (Fig. 2). Finally, the SPRED family of proteins contains a Sprouty related 
domain that can bind Ras. The SPRED/Ras complex recruits Raf to the cell membrane, 
whereas Raf activation through phosphorylation of its Serine338 site is blocked by 
SPRED. This results in termination of Ras/MAPK signaling [40]. SPRED is a substrate 
of SHP2 which dephosphorylates the SPRED activating tyrosine sites to restore 
Ras/MAPK signaling pathway activity (Fig. 2) [41].   
 
1.3.2 The role of SHP2 in the Src family kinase signaling pathway 
SHP2 interaction with the members of the Src family of kinases (SFKs) is complex 
and sometimes tissue specific. For example, after recruitment by the α6β4 integrin, 
SHP2 binds Fyn and dephosphorylates its negative regulatory tyrosine site. Active Fyn 
promotes integrin signaling leading to cell growth, migration, and survival [42]. In 
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hematopoietic cells, the Grb2 associated binder protein 2 (Gab2) recruits both SHP2 
and Lyn after G-CSF stimulation. SHP2 then activates Lyn, which in turn induces cell 
proliferation [43]. Once the SFKs are activated, they can initiate a negative feedback 
loop by phosphorylating the CSK binding protein (Cbp) SH2 binding sites. Cbp then 
binds the Src kinase and recruits the C-Src tyrosine kinase (CSK). CSK is a negative 
regulator of the SFKs, and normally resides in the cytoplasm [44]. Cbp complex 
formation with SFKs and CSK results in phosphorylation of the SFKs c-terminal 
inhibitory tyrosine site by CSK, thus terminating Src signaling [44]. SHP2 can interfere 
with this negative regulatory mechanism by dephosphorylating Cbp to block relocation 
of CSK to the cell membrane (Fig. 3) [45].   
 
 
Figure 2. Function of SHP2 in Ras/MAPK kinase signaling pathway. SHP2 is recruited 
to the cell membrane by an active RTK and binds the Grb2/SOS complex to initiate 
Ras/MAPK signaling. SHP2 also dephosphorylates the Sprouty, SPRED, and 
p120RasGAP binding sites to prevent their recruitment to the cell membrane and 
termination of Ras/MAPK signaling.  
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Figure 3. Function of SHP2 in Src kinase signaling pathway. SHP2 dephosphorylates 
the CSK binding site on both Paxillin and Cbp, leading to Src activation. 
 
 
1.3.3 The role of SHP2 in the PI3K and Jak/STAT1 signaling pathway 
SHP2 functions differently in the Phosphatidylinositol-4, 5-bisphosphate 3-kinase 
(PI3K) signaling pathway depending on the activating growth factor and tissue type. 
After stimulation with IGF, PDGF, or Thrombopoietin, SHP2 associates with the PI3K 
subunit p85 and induces Akt activation in mouse fibroblasts, glioblastoma cells and 
megakaryocytes, promoting cell proliferation and survival [46-48]. On the other hand, 
EGF stimulation causes the opposite effect. In this case, SHP2 dephosphorylates the 
p85 binding sites on Gab1, leading to decreased p85/SHP2/Gab1 association and Akt 
phosphorylation [49, 50]. These opposing effects on PI3K signaling further add to the 
complexity of SHP2 function in signal transduction. 
The Janus kinase (Jak)/Signal Transducers and Activators of Transcription 1 
(STAT1) signaling pathway activation by type I and II interferons (IFN) elicits a strong 
anti-proliferative response which is negatively regulated by SHP2 [51]. Indeed, SHP2 
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dephosphorylates STAT1 after Jak1/2 phosphorylation, disrupting the formation of 
STAT1 dimers and translocation to the nucleus [52]. This inhibitory mechanism is 
particularly deleterious in post surgery melanoma patients treated with IFNα adjuvant 
therapy. Previous work in our lab has shown that SHP2 can restore Ras/MAPK 
signaling pathway activity post IFN-α2b treatment which significantly curtails the anti-
proliferative effects of IFNα therapy [53]. In addition, SHP2 can also regulate STAT1 in 
a phosphatase independent manner by binding and sequestering non-phosphorylated 
STAT1 in the cytoplasm [54]. 
 
1.4 SHP2 and cancer 
SHP2 is a cancer essential gene in certain types of carcinomas. For example, SHP2 
is required for survival of tumor initiating cells, tumor growth, and metastasis in Her2 
positive and triple negative breast cancers [55, 56]. SHP2 is also required to potentiate 
EGFRvIII mediated cellular transformation in glioblastoma and SHP2 knock-down in 
these cells hinders cell-cycle progression and EGFRvIII mediated cell signaling [57]. 
Moreover, SHP2 is a proto-oncogene. Activating SHP2 mutations in the N-SH2 binding 
domain or the PTP domain disrupt the auto-inhibitory mechanism, conferring 
constitutive activity to the PTP catalytic domain (Fig. 4). These GOF SHP2 mutants can 
induce myeloproliferative disorders and act as leukemic oncogenes. They have been 
identified in 35% of juvenile myelomonocytic leukemia, 10% of childhood 
myelodysplastic syndromes, 7% of B-cell acute lymphoblastic leukemia, 4% of acute 
myelogenous leukemia, and a small percentage of carcinomas [58, 59].  
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Figure 4. GOF SHP2 mutations. The majority of the GOF function SHP2 mutations are 
located in the N-SH2 or PTP binding domain and disrupt the auto-inhibitory mechanism, 
conferring constitutive activity to the PTP catalytic domain. 
 
Since SHP2 is involved in multiple signaling pathways, the acquisition of an 
activating mutation results in a myriad of phenotypic changes. Indeed, GOF SHP2 
mutations partly induce cellular transformation by upregulating the Ras/MAPK and Src 
signaling pathway, leading to increased cell proliferation and survival [60, 61]. In 
myeloid progenitor cells, GOF SHP2 mutants promote cytokine independent survival 
while causing hypersensitivity to GM-CSF and IL-3 [62]. Activating SHP2 mutants also 
induce centrosome amplification which disrupts cell division and causes genomic 
instability [63]. In addition, mutated SHP2 causes an expansion of the myeloid 
progenitor cell compartment by blocking the differentiation of early stage hematopoietic 
progenitors. This process also causes anemia by disrupting normal erythropoiesis [64].   
Activating SHP2 mutations have been identified at low frequencies in several cancer 
types such as lung (1.81%), colon (5.98%), and endometrium (4.27%) according to the 
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COSMIC database as of April 2014, but might play an important role nevertheless. For 
example, in a study performed by Sturla et al, GOF SHP2 mutations were identified in 
2% of glioblastoma patient samples, and protected tumor cells against senescence [65]. 
The potential role of SHP2 as an oncogene in carcinoma is still unknown, and further 
study is required to understand the contributions of GOF SHP2 mutations to epithelial 
tumorigenesis. 
 
1.5 Lung cancer  
Lung cancer is the most prevalent type of cancer in the United States. According to 
the American cancer society, there will be about 224,210 new cases in 2014, leading to 
approximately 159,260 deaths (about 27% of all cancer deaths). Lung cancer is divided 
in two classes, small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC). 
About 80% of cases fall under the NSCLC category, which is further subdivided in three 
groups: squamous cell carcinoma, adenocarcinoma, and large cell carcinoma [66]. 
Each group presents unique histological features and arises in different areas of the 
lung. Adenocarcinoma is the most commonly indentified subtype in patients. Multiple 
driver oncogenes have been identified in adenocarcinoma (Fig. 5), and have been 
targeted for drug development [67]. Unfortunately, the majority of patients develops 
drug resistance and relapses [68-71]. Moreover, in about 40% of cases the transforming 
factor is unknown, highlighting an urgent need for alternative therapies. The 
identification and targeting of the cell of origin of lung cancer could provide a new 
avenue for therapeutic treatment. 
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Figure 5. Common driver oncogenes in adenocarcinoma. Adenocarcinoma is a subtype 
of non small cell lung cancer. Several driver oncogenes have been identified and 
provide valuable targets for drug development. 
 
The concept of a lung cancer cell of origin has generated a lot of interest, and 
multiple research teams have tried to identify this cell population. Previous studies using 
lung tissue have established a novel cell type located at the bronchioloalveolar ductal 
junction with positive expression of both the Clara cell antigen 10 (CC10) and the 
alveolar type II marker Surfactant protein C (SPC) [72, 73]. These cells are called 
bronchioloalveolar stem cells (BASCs), and while normally quiescent, become activated 
following injury and give rise to type I and II pneumocytes. Further work using mouse 
models supported that BASCs are the cell type from which adenocarcinomas could 
arise [72, 73]. In squamous cell carcinoma, progenitor tracheal basal cells are the 
tentative candidate for cell of origin due to similar patterns of gene expression and 
histological features, but further work is required to confirm this hypothesis [72]. 
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The SCLC cell of origin has been difficult to identify due to tumors often exhibiting 
mixed cell types and cell surface markers. In general, SCLC is thought to arise from 
neuroendocrine progenitor cells based on shared patterns of neuroendocrine markers 
and gene expression [72, 74]. This hypothesis was supported by data from the Kim lab 
using a mouse model where deletion of the p53 and Rb genes in neuroendocrine cells 
located in the lung epithelium resulted in hyperproliferative lesions [74]. 
Aside from BASCs and neuroendocrine progenitor cells, cancer stem cells have also 
been proposed as the cell of origin for lung cancer. Previous studies have identified a 
novel lung cell type termed side population (SP) which displays characteristics similar to 
stem cells described in other tumor types [75]. Lung SP cells efflux Hoechst 33342 dye 
and express stem cell markers such as CD133, ALDH, and CD 44 [75, 76]. Lung SP 
cells are usually in a quiescent state, are resistant to chemotherapy, and express genes 
involved in self-renewal such as Sox2, Nanog, and Oct 4 [77]. Interestingly, this side 
population is enriched with tumor initiating cells and demonstrates self renewal, tumor 
repopulating capacity, and have been identified in lung patient tumor samples [78, 79]. 
Based on this evidence, a strong case can be made that lung cancer is initiated by the 
deregulation and uncontrolled division of lung cancer stem cells and that lung SP cells 
could provide a valid therapeutic target for lung cancer treatment [75]. 
The identification of the lung cancer cell of origin can provide valuable insight into 
lung tumorigenesis and could open up new avenues for drug development. Extensive 
research has been done to characterize these cells, but at this stage further study is 
required to better understand and fully determine their roles in lung carcinogenesis in 
order to target them for therapeutic treatment. 
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1.6 The epidermal growth factor receptor 
The EGF receptor is a member of the ErbB tyrosine kinase family, and is composed 
of a cytoplasmic protein tyrosine kinase domain, a single membrane spanning region, 
and an extracellular ligand binding domain (Fig. 6). Upon ligand binding by a member of 
the EGF family of ligands, the EGF receptor homo or hetero-dimerizes with a member 
of the ErbB family resulting in intrinsic kinase trans-activation [80]. The auto-
phosphorylation of the EGFR c-terminal tyrosine docking sites recruits a variety of 
adapter proteins, kinases, and phosphatases, which induce the activation of several 
signaling pathways involved in cell growth, differentiation, survival and more [81].  
 
1.6.1 EGFR activation induces cell signaling 
 
1.6.1.1 EGFR and the Ras/MAPK signaling pathway 
EGFR activation upon ligand binding and dimerization induces the Ras/MAPK cell 
signaling pathway by recruiting the Grb2/SOS complex to the cell membrane [82]. SOS 
is a guanine nucleotide exchange factor that catalyzes the conversion of inactive GDP-
bound Ras to active GTP-bound Ras. Ras binds multiple targets, but its main function is 
to activate Raf by inducing a conformational change that disrupts Raf association with 
the inhibitory protein 14-3-3. This triggers activation of the Raf/Mek/MAPK signaling 
chain, leading to MAPK translocation to the nucleus and activation of transcription 
factors that promote cellular growth, proliferation, differentiation and survival [83-85].  
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1.6.1.2 EGFR and the Src family kinase pathway 
Previous studies have described several mechanisms of EGFR mediated SFK 
signaling pathway activation [86]. EGF ligand binding induces translocation of the 
Src/SHC complex to the cell membrane whereas SHC binds active EGFR, leading to 
Src activation [87]. SHC is an adapter protein which associates with multiple partners 
upon phosphorylation by RTKs [88]. EGF stimulation can also recruit SHP2 to the cell 
membrane, where it binds to protein complexes composed of Gab1, Paxillin, CSK, or 
Src. SHP2 dephosphorylates the CSK binding sites on Paxillin, leading to Src activation 
(Fig. 3) [34]. Src activation by EGFR also triggers a positive feedback loop whereas 
active Src can in turn phosphorylate and promote EGFR activity, resulting in increased 
cell proliferation, migration, and anchorage-independent growth [86, 89]. 
 
1.6.2 EGFR and cancer 
EGFR over expression or amplification in several types of cancer including breast, 
glioblastoma, and gastrointestinal carcinoma is a negative prognosis marker of survival 
in patients [90-92]. Moreover, GOF EGFR mutations are oncogenic and induce cellular 
transformation. They have been identified predominantly in lung cancer, but are present 
in additional cancer types including malignancies of the central nervous system 
(4.77%), prostate (3.94%), intestine (4.46%), and more according to the COSMIC 
database as of April 2014.  
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Lung cancer is divided in two histological subtypes, non-small cell lung cancer and 
small cell lung cancer. Non small cell lung cancers make up about 80% of cases, and 
are further sub-divided into three groups, squamous cell carcinoma, large cell 
carcinoma, and adenocarcinoma [93]. GOF EGFR mutations are present in about 
27.54% of lung adenocarcinoma cases according to the COSMIC database. 
Interestingly, patients with GOF EGFR mutations are usually never smokers or females 
of Asian descent. The mechanisms underlying this apparent sensitivity have not been 
fully elucidated [94-96].  
 
1.6.2.1 Gain of function EGFR mutations 
GOF EGFR mutations are classified in two main groups: extracellular domain 
mutations or tyrosine kinase mutations. The prevalence of these two classes of 
mutations differs based on cancer type. 
Extracellular domain mutations. 
Previous studies have identified three types of EGFR mutations with extracellular 
domain deletion. They are classified based on the extent of the extracellular domain 
deletion. The first type, called EGFRvI, exhibits a complete deletion of the extracellular 
domain while the second type, EGFRvII, contains an 83 amino acid deletion in domain 
IV [97]. This mutation does not appear to contribute to tumorigenesis [97]. The third and 
most commonly identified type, EGFRvIII, lacks domain I and II of the extracellular 
ligand binding domain (Fig. 6), and is often amplified. This mutation confers constitutive 
kinase activity and is common in glioblastoma (30-50% of cases) and has been reported 
in about 5% of squamous cell carcinoma patients [98-100].  
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Tyrosine kinase domain mutations 
About 90% of tyrosine kinase domain mutations are sub-divided in two groups. The 
first group contains a small deletion, usually amino acids 746-750, in exon 19. The 
second group contains a missense mutation on exon 21 substituting leucine for arginine 
at codon 858 [97]. Multiple variants of these two mutations have been described, and 
include larger deletions, point mutations and insertions, notably in exon 20 (Fig. 6) 
[101]. Interestingly, tyrosine kinase domain mutations are usually identified in lung 
cancer, and tend to be mutually exclusive with other oncogenes such as KRAS [97]. 
 
Figure 6. Common GOF EGFR mutations in glioblastoma and lung cancer. Extracellular 
domain mutations are often identified in glioblastoma and exhibit partial to entire 
deletion of the extracellular domain. Kinase domain mutations are usually identified in 
lung cancer, and can be found in multiple exons of the tyrosine kinase domain. 
 
1.6.2.2 EGFR as a therapeutic target in NSCLC  
The establishment of GOF EGFR mutations as a valid therapeutic target in NSCLC 
led to the development of multiple specific tyrosine kinase inhibitors (TKIs). Gefitinib 
(Iressa) was the first of its kind and showed promising anti-tumor potential in vitro and in 
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vivo. This small molecule inhibitor blocks receptor autophosphorylation by competing 
with ATP for binding to the intracellular ATP binding pocket of mutant EGFR [102]. 
Gefitinib treatment abrogates GOF EGFR mutant signal transduction leading to 
decreased cell growth, proliferation and survival [103]. These effects are mediated 
through multiple mechanisms. For example, Gefitinib promotes G1 phase arrest through 
upregulation of p27 and suppresses angiogenesis by decreasing VEGF levels [104, 
105]. Gefitinib also decreases cell survival by upregulating BAD, a pro-apoptotic 
member of the Bcl-2 family of apoptosis regulators [106].  
Phase I clinical trials reported Gefitinib is well tolerated in patients, with most side 
effects falling within Common Toxicity Criteria grade 1 or 2 [107]. Several phase II trials 
proved the efficacy of Gefitinib in patients with NSCLC [107]. Of these trials, the Iressa 
dose evaluation in advanced lung cancer 1 (IDEAL1) trial demonstrated a response rate 
of 18.4% with a median progression free survival of 2.7 months and an overall survival 
rate of 7.6 months, establishing Iressa as a valid therapeutic agent in the treatment of 
advanced lung cancer [108]. Based on these results, two phase III clinical trials termed 
Iressa NSCLC Trial Assessing Combination Treatment (INTACT) 1 and 2 were 
undertaken to compare a combination of Cisplatin and Gemcitabine with Gefitinib or a 
combination of Carboplatin and Paclitaxel with Gefitinib to chemotherapy alone. 
Unfortunately, Gefitinib treatment did not improve overall survival in patients compared 
to placebo controls [70, 71]. Despite these results, Iressa was approved as a third line 
therapy after failure of Docetaxel and platinum based chemotherapies by the FDA on 
May 3rd 2003 [109]. An important point is that these clinical trials were performed 
without checking the mutation status of the EGF receptor [110]. Subsequent studies 
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demonstrated that lung cancer patients carrying a GOF EGFR mutation have a 
significantly higher response rate and time to disease progression compared to patients 
with wild type EGFR [111, 112]. The Iressa pan-Asia study (IPASS) further validated 
these results by describing a 71.2% objective response rate in patients carrying a GOF 
EGFR mutation. Based on this data, Gefitinib is administered as a first line therapy to 
East Asian lung cancer patients with GOF EGFR mutations [113]. The success of 
Gefitinib paved the way for the development of a host of novel agents ranging from 
small molecule tyrosine kinase inhibitors to monoclonal EGFR antibodies [114, 115]. 
 
1.6.2.3 Resistance and relapse to EGFR tyrosine kinase inhibitors 
Despite the initial efficacy of EGFR tyrosine kinase inhibitors, several studies have 
shown that the majority of patients stop responding to treatment and relapse. These 
reports prompted a search to determine the mechanisms of acquired resistance to 
EGFR tyrosine kinase inhibitors. Pao et al was one of the first groups to describe the 
T790M mutation in patients resistant to Gefitinib treatment [116]. This mutation is 
present concurrently with Gefitinib sensitive GOF EGFR mutations, and induces a 
conformational change that interferes with Gefitinib binding and significantly increases 
receptor affinity for ATP [117-119]. Acquisition of the T790M mutation occurs in about 
50% of lung cancer patients treated with EGFR tyrosine kinase inhibitors and is the 
main cause of TKIs drug resistance [120]. Additional mechanisms of resistance have 
been described, including activation of alternative tyrosine kinases (IGF-1R and PI3K) 
or c-Met amplifications [121-123]. While multiple approaches aiming to overcome these 
mechanisms of resistance are currently being studied, there is an urgent need for the 
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identification of novel therapeutic targets to develop treatments for patients who have 
failed both chemotherapy and EGFR targeted therapy [67, 124]. 
 
 
1.7 Mouse models 
Mouse models are an invaluable tool to study the effects of targeted gene alterations 
on development and disease. Since the generation of the first genetically modified 
animals in the early 70s, mouse models have become the de facto option to study gene 
modification in vivo [125, 126]. There are currently multiple approaches available to 
generate mouse models.  
 
1.7.1 Techniques for mouse model generation 
The knock-out system causes partial to total deletion of the gene of interest, 
resulting in the expression of a non-functional truncated protein or no protein at all [127]. 
On the other hand, the knock-in system makes use of homologous recombination to 
insert a mutated gene in its original locus, replacing the wild type gene in the process 
[128]. These two approaches have many advantages. Targeted insertion/deletion of the 
gene of interest in its original locus ensures gene expression is comparable to wild type 
and also prevents disruption of critical genes, a common issue when using random DNA 
integration. The main drawback with these approaches is that the gene modification is 
irreversible, so dependency of the observed phenotype on sustained gene 
expression/deletion cannot be determined. This issue was corrected with the 
development of inducible transgenic mouse models [128]. One of the main approaches 
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uses the Dox-inducible reverse tetracycline transcription regulation system. In the 
presence of Dox, the reverse tetracycline transactivator (rtTA) binds the tet operon 
promoter (tetO) and induces transcription of the transgene [129]. Transgene expression 
can be restricted to the organ or cell type of interest by expressing rtTA under the 
control of a tissue specific promoter [130-132]. Since we are interested in lung cancer, 
we acquired a mouse strain developed by the Whitsett group, which uses the Clara cell 
secretory promoter (CCSP) to restricts transgene expression to type II pneumocytes in 
bitransgenic animals [131]. 
 
1.7.1.1 Cre recombinase mediated cassette exchange system 
The generation of transgenic, knock-in or knock-out models is a time consuming and 
costly process. Each new founder line needs to be fully characterized before use, and 
the random integration and expression levels of DNA in transgenic mouse models 
makes comparison of transgene expression between two different mouse models 
unreliable. To address these issues, the Wahl group designed the Cre-recombinase 
mediated cassette exchange system (RMCE) [133]. They started by designing a novel 
LoxP site that differs from the original LoxP site by three nucleotides to avoid 
recombination between the two sites. They then generated a cassette where the 
hygromycin phosphotransferase-thymidine kinase (HyTK) was flanked by the original 
and novel LoxP sites (termed L2 and L3). The cassette was inserted in the DHFR locus 
by homologous recombination or at random sites in the genome through single copy 
integration using a retrovirus [133]. After confirming the presence and expression of the 
transgene, RMCE was performed using a donor LoxP target. RMCE efficiently induced 
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site specific recombination and incoming transgene showed expression levels 
comparable to original transgene (Fig. 7) [133]. These results establish RMCE as an 
excellent tool to quickly and efficiently generate novel transgenic mouse models with 
comparable gene expression.  
 
Figure 7. Cre recombinase mediated cassette exchange system. The gene is flanked by 
oppositely oriented hetero-specific LoxP sites and inserted in the genome. In the 
presence of Cre recombinase, the corresponding LoxP sites from the original cassette 
recombine with the LoxP site on the replacement cassette replacing the original gene 
with the DNA from the donor plasmid.   
 
1.7.2 SHP2 mouse models 
To determine the role of SHP2 in normal cellular development and cancer, multiple 
mouse models have been generated. One of the first models used a knock-out 
approach to delete part of the N-SH2 binding domain (SHP2∆46-110). Homozygous 
SHP2∆46-110 embryos did not survive past E11.5. At an earlier time point, homozygous 
SHP2∆46-110 embryos were present but displayed severe developmental abnormalities 
and growth retardation compared to wild type littermates [134]. Further study revealed 
that the morphological abnormalities seen in SHP2∆46-110 embryos were most likely 
caused by the impaired ability of the mutant SHP2 to activate the Ras/MAPK pathway 
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downstream of activated PDGFR and FGF [134]. To determine the effect of pan-SHP2 
knock-out in adult mice, Bauler et al developed a tamoxifen inducible estrogen receptor-
2 cre transgenic mouse model with homozygous floxed ptpn11 (ptpn11fl/fl ert2-cre) 
[135]. Adult mice displayed impaired hematopoiesis and osteoclastogenesis, cartilage 
abnormalities, as well as pronounced kyphosis and scoliosis [135]. Targeted SHP2 
knock-out in type II alveolar epithelial cells using the SPC-rtTA/tetO-Cre/SHP2fl/fl mouse 
model caused spontaneous interstitial fibrosis induced by impaired surfactant protein 
metabolism [136]. These mouse modeling studies established SHP2 as an essential 
player in embryonic development and survival. Moreover, SHP2 also plays a key role in 
adult animals, and is required for proper bone and lung epithelial cell homeostasis as 
well as hematopoiesis.   
Aside from its role in development and normal cellular function, SHP2 is also an 
important factor in cancer. Since SHP2 is a known leukemic oncogene, multiple mouse 
models were developed to study the role of SHP2 in leukemogenesis [17, 137]. The Qu 
and Neel groups both generated a knock-in GOF SHP2 mutant mouse model 
(Ptpn11D61G/+) to determine the mechanism of leukemogenesis and study Noonan 
syndrome in vivo. Several Ptpn11D61G/+ organs displayed elevated pErk1/2 and pAkt 
levels and hematopoietic stem cells (HSCs) showed hypersensitivity to GM-CSF and IL-
3 [61, 138]. Ptpn11D61G/+ mice also showed activation of quiescent HSCs, development 
of myeloproliferative disease (MPD) and splenomegaly [61]. Interestingly, Ptpn11D61G 
mediated MPD was dependent on the presence of Gab2 [61]. A knock-in mouse model 
using the GOF Ptpn11E76K mutant (Ptpn11E76Kneo/+/Mx1-Cre+) exhibited a similar 
phenotype to Ptpn11D61G/+ mice with the development of MPD. In addition, these mice 
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progressed to leukemia and displayed severe impairment of hematopoietic 
differentiation and GM-CSF/IL-3 hypersensitivity [63]. These mouse modeling studies 
determined that SHP2 co-localizes with centrosomes, and that HSCs from Ptpn11E76K 
mice display altered numbers of centrosomes, leading to abnormal cell division and 
genomic instability [63]. These studies bring an important insight into the mechanism of 
GOF SHP2 mutant driven leukemogenesis and further our understanding of these 
diseases.  
While the contribution of GOF SHP2 mutations in mouse models of leukemia has 
been studied, no GOF SHP2 mutant mouse model of carcinoma asides from the one 
described in this project are currently available. GOF SHP2 mutations are present in a 
small percentage of solid cancers, and merit further investigation to determine whether 
SHP2 contributes to carcinogenesis and acts as a proto-oncogene in carcinoma. 
 
1.7.3 GOF EGFR mutant lung cancer mouse models 
The prevalence of GOF EGFR mutations in patients with NSCLC led to a strong 
push to develop transgenic mouse models to study this disease. In 2006, four mouse 
models were described by the Wong and Varmus lab, and expressed either the exon 19 
LREA deletion Del 747-753, the exon 19 deletion  Del 747-752, or the exon 21 
EGFRL858R point mutation [139, 140]. All four models used the reverse tetracycline 
transactivation system to direct transgene expression. In this system, bitransgenic 
animals carry a construct which contains the CCSP promoter and the gene for the 
reverse tetracycline transactivator and a construct that contains the gene of interest 
under the control of the tetO promoter. When doxycycline is administered to the mice 
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either through feed or water, Dox binds to rtTA which can then in turn bind the tetO 
promoter and induce expression of the transgene [131]. This system is highly versatile, 
and allows for reversible targeted expression of the transgene in a variety of tissue 
types depending on the promoter.   
Dox induction of bitransgenic CCSP-rtTA/tetO-EGFRDel 747-753, CCSP-rtTA/tetO-
EGFRDel 747-752, CCSP-rtTA/tetO-EGFRL858R mice led to formation of hyperplastic lesions 
with progression to adenocarcinoma at later time points. Tumor burden could be cleared 
by Dox withdrawal, treatment with Erlotinib or with Cetuximab, demonstrating that tumor 
cells are dependent on sustained GOF EGFR mutant signaling for survival [139, 140]. 
These transgenic mouse models provide an excellent tool to better understand the 
mechanisms of GOF EGFR mutant driven lung carcinogenesis and to identify novel 
therapeutic targets and mechanisms of drug resistance [141-143].   
 
1.8 Introduction conclusions 
The functions of the protein tyrosine phosphatase SHP2 and its role in cancer 
have been extensively studied since its discovery. SHP2 is a well established 
leukemic oncogene and GOF SHP2 mutations cause activation of the Ras/MAPK 
and Src cell signaling pathway, which can have a transforming effect in 
hematopoietic progenitor cells. The function of SHP2 as a mediator of EGFR cell 
signaling has also been researched, and it has become clear that the EGF 
receptor relies on SHP2 for signal transduction. GOF EGFR mutations act as 
oncogenes in lung epithelial cells and are commonly found in non-smoker and 
Asian women afflicted with NSCLC. While several tyrosine kinase inhibitors 
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targeting EGFR have been developed to treat patients, the majority acquire drug 
resistance and relapse, highlighting an urgent need for the identification of 
additional therapeutic targets. Since wild type EGFR relies on SHP2 to promote 
cell signaling, it begs the question of whether GOF mutant EGFR also requires 
SHP2 to induce and sustain lung tumorigenesis. If GOF EGFR mutants were to 
actively rely on SHP2 for cell signaling, targeting SHP2 could provide a useful 
alternative to EGFR tyrosine kinase inhibitors and could provide a potential target 
for drug development. Several studies have supported this idea, and shown that 
SHP2 inhibition in a drug resistant GOF EGFR mutant dependent lung cancer 
cell line can significantly decrease cell proliferation [144]. Further work is required 
though to confirm these results and validate SHP2 as a therapeutic target in GOF 
EGFR mutant dependent lung cancer. 
As mentioned earlier, the role of SHP2 as an oncogene in hematopoietic 
malignancies has been thoroughly described, but the contributions of GOF SHP2 
mutations to carcinogenesis are largely unknown. GOF SHP2 mutations have 
been identified in a small percentage of multiple types of carcinoma, notably lung 
cancer. GOF SHP2 mutations have been found in every lung cancer subtype. 
Given the function of SHP2 as a promoter of cell signaling, it is possible that the 
GOF SHP2 mutations found in lung cancer patients are actually contributing to 
carcinogenesis, and could provide a novel therapeutic target for drug 
development. At this stage, little research has been done to investigate this 
hypothesis, so the question remains to be answered. 
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Chapter 2: Inhibition of SHP2 impairs oncogenic activity of EGF receptor mutants 
in non-small cell lung cancer 
 
2.1 Abstract 
Gain of function EGFR mutations have been identified in 15-25% of lung 
adenocarcinomas and are targets for therapeutic treatment. EGFR tyrosine kinase 
inhibitors elicit a strong initial response, but eventually the majority of patients stop 
responding to treatment and relapse. Multiple approaches have been evaluated to 
overcome drug resistance, but there is still an urgent need for the identification of novel 
therapeutic targets to treat lung cancer. SHP2 is an important mediator of EGFR signal 
transduction, and positively regulates the Ras/MAPK and Src signaling pathway. In this 
study, we determined whether SHP2 also plays a role in GOF EGFR mutant signaling. 
SHP2 inactivation using the SHP2 PTP inhibitor SPI-112me, a dominant negative SHP2 
mutant, or SHP2 knock-down suppressed cell proliferation and Ras/MAPK signaling in 
GOF EGFR mutant dependent HCC827 and H1975 lung cancer cells. To asses the role 
of SHP2 in a mouse model of EGFR driven lung cancer, we generated a Dox inducible 
transgenic mouse model which expresses the dominant negative PTP-defective 
SHP2CSDA mutant in type II pneumocytes under the control of the Clara cell secretory 
protein promoter. Dox induced bitransgenic CCSP-rtTA/tetO-EGFRL858R mice exhibited 
higher levels of pSrc and pErk1/2 compared to wild type controls. SHP2CSDA expression 
in tritransgenic CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice suppressed activation 
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of both kinases. Importantly, SHP2CSDA expression significantly delayed EGFRL858R 
induced tumor formation and progression. SHP2CSDA expression also reduced pGab1 
levels and caused a dissociation of the Gab1/SHP2 complex. This can explain the 
decreased phosphorylation of pErk1/2 and Src seen in tritransgenic mice, and could be 
the mechanism of action of SHP2CSDA. These results indicate that SHP2 activity is 
critical for GOF EGFR mutant mediated tumorigenesis, and establish SHP2 as a 
potential therapeutic target in NSCLC. 
 
2.2 Introduction  
Lung cancer is the most prevalent type of cancer in the United States. The American 
Cancer Society estimates there will be about 224,210 new cases in 2014, leading to 
approximately 159,260 deaths (about 27% of all cancer deaths). Despite extensive 
research to develop novel therapeutic treatments and to improve understanding of the 
biology of this disease, the mortality rate for lung cancer remains high. This is partly 
caused by diagnosis at an advanced stage which limits treatment options and by patient 
relapse after therapeutic intervention [145, 146]. Lung cancer is divided in several 
subtypes, with NSCLC making up about 80% of all cases. NSCLC are further classified 
into three groups, adenocarcinoma, large cell carcinoma, and squamous cell carcinoma. 
Adenocarcinoma is often initiated by the activation of a single oncogene. Kras, Alk, and 
EGFR are the most commonly identified drivers of adenocarcinoma (Fig. 5) [147, 148]. 
In this study, we focused on GOF EGFR mutant dependent lung cancer. According to 
the COSMIC database about 27.54% of lung cancers carry GOF EGFR mutations. 
Although patients initially respond to EGFR tyrosine kinase inhibitor treatment, most of 
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them relapse and develop drug resistance through multiple mechanisms, including 
acquisition of the “gatekeeper” T790M mutation in about 50% of cases [149]. This 
mutation alters the conformation of the ATP binding pocket and interferes with Gefitinib 
and Erlotinib binding while significantly increasing the affinity of EGFR for ATP. Despite 
the development of second and third generation tyrosine kinase inhibitors that 
overcome the effects of the T790M gatekeeper mutation, disease progression still 
occurs through acquisition of additional drug resistance mechanisms [124]. These 
observations highlight an urgent need for the identification of new therapeutic targets to 
treat GOF EGFR mutant dependent lung cancer patients. 
SHP2 is a cancer essential gene in multiple cancer types and is required to promote 
cell transformation, survival, growth and metastasis [55, 57]. SHP2 is an important 
component of the EGFR signaling pathway as well. Previous work has shown that 
deletion of the N-SH2 binding domain blocks SHP2 relocation to the cell membrane 
leading to decreased activity of the Raf and Mek kinases following EGF stimulation 
[150]. Moreover, SHP2 knock-down in lung cancer cell lines expressing wild type EGFR 
also decreases basal levels of pErk1/2 [151]. The importance of SHP2 in EGFR 
mediated signal transduction led us to investigate whether SHP2 activity is also required 
to promote GOF EGFR mutant signaling and if targeting SHP2 could negatively impact 
cell growth and survival. To answer these questions, we used an in vitro approach to 
evaluate the effects of SHP2 knock-down or inhibition on cell signaling and proliferation 
in GOF EGFR mutant dependent lung cancer cell lines. We also took advantage of the 
existing EGFRL858R transgenic mouse model to test the effects of a dominant negative 
PTP-inactive mutant of SHP2 (SHP2CSDA) on tumor onset and progression in vivo [140].  
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2.3 Material and Methods  
2.3.1 Transgenic mice  
2.3.1.1 Construction of L3/L2-tetO vector 
The L3/L2-tetO vector was constructed by Dr Noreen Luetteke at the Moffitt Cancer 
Center Transgenic Animal Core using the transgenic vector tet-op-mp1 as a backbone. 
This vector was kindly provided by Dr. Katerina Politi and contains the tetO promoter, 
the mouse protamine1 intron and the polyadenylation sequences [140]. Two tandem 
repeats of the 1.2 Kb chicken beta globin insulator (cHS4) were subcloned into the XhoI 
site upstream of the tetO response element to limit the risk of leaky transgene 
expression [152]. The heterotypic loxP sites were synthesized as oligonucleotides 
based on published sequences and annealed to produce double-stranded adaptors with 
compatible overhangs to permit subcloning into restriction sites and facilitate screening 
[133]. The L3 mutant loxP adaptor contains 5’ XhoI and 3’ SalI sticky ends and was 
subcloned into the XhoI site upstream of the cHS4
 
insulators. The L2 wild-type loxP 
adaptor contains 5’ NotI and 3’ EagI sticky ends and was subcloned in reverse 
orientation into the NotI site of the tet-op-mp1 vector downstream of the polyA signal. 
The integrity and orientation of the loxP sites in the final vector (L3/L2-tetO) were 
confirmed by DNA sequencing. 
 
2.3.1.2 Transgene microinjection 
The DNA fragment containing the human SHP2CSDA mutant was previously 
described and excised from a pCDNA3.1 vector and subcloned into the EcoRV site 
between the tetO and polyA sequences of L3/L2-tetO plasmid [34]. The completed 
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SHP2CSDA transgene was excised from the vector by digestion with BssHII and isolated 
by agarose gel electrophoresis followed by EluTrap electroelution and EluTip 
purification. Ethanol precipitated DNA was resuspended in sterile microinjection buffer 
(10 mM Tris-HCl, 0.1 mM EDTA, pH 7.5) and microinjected at 3 ng/ µl into 0.5 dpc 
fertilized FVB/N zygotes per standard methods. Zygotes were then surgically implanted 
into the oviducts of 0.5 dpc pseudopregnant CD-1 females. Offspring were tail biopsied 
at weaning and genotyped by PCR and slot blot hybridization to identify transgenic 
lines. This work was performed by Dr. Liwei Chen and Jie Wu from the Wu laboratory 
and the Moffitt Cancer Center Transgenic Core. 
 
2.3.1.3 Genotyping of tetO-SHP2CSDA transgenic mice 
TetO-SHP2CSDA mice were genotyped by PCR using the GoTaq® Hot Start Green 
Master Mix (Promega) and the following primers: SHP2T1, 5’- 
AGACGCCATCCACGCTGTTTTGAC-3’ and SHP2T2, 5'-
TCTCTTTTAATTGCCCGTGATGTT-3’. PCR reaction was performed in a total volume 
of 25 µL using the following conditions: 4 min denaturation at 94°C, 35 cycles of 94°C 
for 30 sec, 57°C for 30 sec, and 72°C for 30 sec wi th a final extension step of 72°C for 4 
min yielding a 430-bp PCR fragment. 
 
2.3.1.4 CCSP-rtTA and EGFRL858R transgenic mice 
CCSP-rtTA transgenic mice (in inbred FVB/N background) were provided by Dr. 
Jeffrey A. Whitsett. tetO-EGFRL858R mice (in Bl6 background) were obtained from the 
NCI/NIH mouse repository. Animals were maintained in pathogen-free housing 
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conditions. Rodent chow containing 200 mg/kg Dox (Dox diet, Bio-Serv) was used to 
activate the reverse tetracycline transactivator. Animal studies and care were approved 
by the Institutional Animal Care and Use Committee of the University of South Florida 
and followed institutional and national guidelines. 
 
2.3.2 RT-PCR analysis  
Tissue samples were snap frozen in liquid nitrogen. RNA was extracted using Trizol 
reagent (Life Technologies) according to manufacturer protocol. Samples were treated 
with DNase I (Life Technologies) to avoid DNA contamination. RT-PCR was performed 
using the SuperScript One-Step RT-PCR Platinum Taq system (Life Technologies) with 
the following primers: SHP2F1: 5'-GGTTGGACAAGGGAATACGG-3’ and SHP2R2: 5'-
AGGGCTCTGATCTCCACTCG-3’. RT-PCR reaction was performed in a total volume of 
50 µL using the following conditions: 30 min cDNA synthesis at 55°C, 4 min 
denaturation at 94°C then 35 cycles of 94°C for 30 sec, 57°C for 30 sec, 72°C for 30 
sec with a final extension step of 72°C for 4 min y ielding a 462-bp fragment.  
 
2.3.3 Cell cultures and reagents 
HCC827 and H1975 cell lines were provided by Dr. Eric Haura and cultured in 
complete RPMI medium1640 (10% fetal bovine serum and1% pen strep) purchased 
from Life Technologies (Carlsbad, CA) at 37°C in 0. 5% CO2. 293T cells were provided 
by Dr. Said Sebti and cultured in complete Dulbecco’s modified eagle medium (DMEM) 
(10% fetal bovine serum and1% pen strep) purchased from Life Technologies 
(Carlsbad, CA) at 37°C in 0.5% CO 2. The human SHP2CSDA GFP tagged fragment or 
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the empty vector control GFP tagged fragment were previously generated in our lab and 
excised from the pcDNA3.1 vector then ligated in the pWP1 transfer vector using PmeI 
digestion according to established protocols [34]. The SHP2CSDA pWP1 transfer vector, 
the packaging plasmid psPAX2 and the enveloped plasmid pMD2.G were transfected in 
293T cells plated in a 6cm plate and grown to near confluence for 6 hours in .5 mL 
Optimem (Life Technologies) and 2 µL Lipofectamine 2000 (Invitrogen) to obtain 
lentivirus. Optimem was removed after transfection and replaced with pen strep free 
complete medium. After 48 hours, viral media was collected and filtered using a .45 µm 
sterile syringe filter (Corning). HCC827 cells were plated in a 6 well plate and grown to 
near confluence. Lentiviral infection was performed in 250 µL pen strep free complete 
medium with 750 µL viral media and 40 µg polybrene for 6 hours. Cells were then 
washed with PBS (Life Technologies) and grown for 2 weeks in complete medium. The 
BD Biosciences FACSVantage DIVA digital cell sorter was used to perform three 
rounds of cell sorting two weeks apart from each other to isolate GFP positive HCC827 
cells. Percentage of GFP positive HCC827 cells was calculated using the DIVA 
software. EGF was purchased from Invitrogen, doxycycline and polybrene from Sigma-
Aldrich, Erlotinib from LC Chemicals, WZ4002 from Selleck, and SPI-112me was 
synthesized in-house at the Moffitt Cancer Center.  
 
2.3.4 RNA interference studies 
2.3.4.1 siRNA  
Cells were plated in 12 well plates (20,000 cells/well) and grown in complete 
medium for 48 hours. Cells were transfected with 25 nM PTPN11 On target plus Smart 
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Pool siRNA or 25 nM On target plus control pool siRNA (Thermo Scientific Dharmacon) 
for 6 hours in 700 µL Optimem with 2 µL Lipofectamine 2000. Optimem was removed 
after transfection and cells were grown for 72 hours in complete medium then serum 
starved for 16 hours prior to protein extraction.  
 
2.3.4.2 shRNA 
The TRIPZ Dox inducible lentiviral human PTPN11 shRNA 1049 and 3469 were 
purchased from Open Biosystems. Lentivirus was obtained using 293T cells according 
to protocol. HCC827 and H1975 cells were infected with either the 1049 or 3469 
lentiviruses and stable clones selected by puromycin treatment. HCC827/1049 and 
HCC827/3469 were plated in 6 well plates (100,000 cells/well) and grown in complete 
medium for 24 hours. ShRNA expression was induced using 2 µg/mL doxycycline for 96 
hours. Cells were then serum starved for 16 hours prior to protein extraction.   
 
2.3.5 Cell proliferation assay 
Cell proliferation was measured using the CellTiter-Glo luminescent cell viability 
assay (Promega). Cells were plated in 96 well black bottom plates (1000 cells/well) and 
grown for 24 hours. HCC827/SHP2CSDA cells and HCC827 SPI-112me treated cells 
were grown for 6 days in 200 µL complete medium. SHP2 knock-down using siRNA or 
shRNA was adjusted to the 96 well plate format and performed as described earlier in 
200 µL complete medium. Cell viability was assayed using 50 µL CellTiter-Glo reagent 
and luminescence was measured using a Wallac 1420 Victor plate reader. 
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2.3.6 Soft agar colony formation assay 
To perform the soft agar colony formation assay, a 1 mL layer of .8% agar (Fisher 
Scientific) in complete medium was poured in each well (6 well plate) and left to solidify 
at room temperature for 20 minutes. Next, a 1 mL layer of 0.4% agar in complete 
medium containing 10’000 cells was gently poured on top of the bottom layer. All agar 
solutions were warmed to 48°C. After solidifying, 5 00 µL of complete medium containing 
2 µg/mL doxycycline was added on top of the agar layer. Cells were grown for 21 days 
and medium was replaced every four days. The number of colonies was assayed by 
MTT staining. 10 mg/mL MTT was added to each well and plate was incubated for 15 
minutes at 37°C. A picture of each well was taken u sing an alpha imager and the 
number of colonies was counted manually. 
 
2.3.7 Immunoblotting, immunoprecipitation and mass spectrometry analysis 
Antibodies to SHP2, Erk1/2, phospho-Erk1/2 (pErk1/2), Gab1, Akt, c-Myc, and β-
actin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).  Flag (rabbit), 
pGab1 (Y627), Phospho-Akt (pAkt), and phospho-Src (pSrc) antibodies were from Cell 
Signaling Technology (Danvers, MA). Src antibody was from Calbiochem (Billerica, MA) 
and M2 Flag antibody was from Sigma (St. Louis, MO).  
Frozen tissues were crushed and lysed with lysis buffer (50 mM Tris-HCl, pH 7.5, 
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 25 mM NaF, 5 mM Na4P2O7, 1 mM 
dithiothreitol, 1 mM Na3VO4, 100 µg/ml of phenylmethylsulfonyl fluoride, 2 µg/ml 
leupeptin, 2 µg/ml aprotinin, and 1% Triton X-100).  Equal amounts of proteins from 
cleared tissue lysates were separated by 10% SDS-polyacrylamide gels and transferred 
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to nitrocellulose filters for immunoblotting.  Flag-tagged SHP2 was immunoprecipitated 
from cleared tissue lysate by using the Flag M2 antibody and Protein-G agarose. Total 
EGFR was immunoprecipitated from cleared tissue lysate supernatants by using the 
EGFR antibody and Protein-A agarose. Immunoblotting was performed as described 
previously [62, 153]. 
Cells were cultured and cell lysates were prepared for immunoblotting or 
immunoprecipitation analyses similar to that described previously [60].  
Protein identification by mass spectrometry was performed by the Moffitt Center Center 
Proteomics Core using standard procedure. Essentially, tryptic peptides from gel slices 
were analyzed with a nanoflow liquid chromatograph coupled to an electrospray ion trap 
mass spectrometer for tandem mass spectrometry peptide sequencing. Five tandem 
mass spectra were collected in a data-dependent manner following each survey 
scan. Sequences were assigned using Mascot (www.matrixscience.com) searches 
against mouse or human (for SHP2CSDA) entries. Results from Mascot were compiled in 
Scaffold. 
 
2.3.8 Histology and immunohistochemistry 
Following euthanasia, mouse lungs were flushed twice with 10 ml PBS and 
insufflated with 10% buffered formalin. After fixation overnight in 10% buffered formalin 
solution at room temperature, paraffin blocks were prepared by standard procedure by 
the Moffitt Cancer Center Tissue Core. Sections (4 µm thick) were stained with 
hematoxylin and eosin (H&E) for histological examination. 
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2.3.9 Microscopy analysis 
Four micron sections of mouse lung tissues were stained with hematoxylin and eosin 
and covered in #1.5 cover glass. These slides were used to acquire whole slide images 
using the Aperio™ (Vista, CA) ScanScope XT with a 20x/0.8NA objective lens at a rate 
of 5 minutes per slide via Basler tri-linear-array. Digital images were stored in the Moffitt 
Network Operations Center and accessible to study participants via the password 
protected Spectrum (Aperio) web-based interface. 
Genie® v1 histology pattern recognition software (Aperio) was used to segment tumor 
from other lung tissues and background. This was completed with a training set of 400 
iterations and careful pathologist quality control. The resultant tumor region area was 
calculated as a percentage of all tissue. This was completed for the isolated tumor 
regions using the Aperio Nuclear® v9.1 algorithm with optimized thresholds (Averaging 
radius = 1 µm; Segmentation Type = 2 Cytoplasmic Rejection; Threshold Type = 1- 
Edge Threshold with weighted Trimming; Min/ Max Nuc Size = 25 µm2/1000000 µm2/; 
RGB stain = 0/ 0.64307/ 0.31756; Positive RGB OD = 0.244583/ 0.509334/ 0.825081).  
 
2.4 Results  
2.4.1 SHP2 inhibition decreases cell proliferation and pErk1/2 levels 
We selected two cell lines to study the role of SHP2 in GOF EGFR mutant 
dependent lung cancer. HCC827 cells carry the LREA deletion in exon 19 and are 
sensitive to EGFR tyrosine kinase inhibitors. On the other hand, H1975 cells express 
both the EGFRL858R point mutation on exon 21 and the gatekeeper T790M mutation 
which confers resistance to Gefitinib and Erlotinib but is sensitive to the irreversible 
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EGFR inhibitor WZ4002. These two cell lines enabled us to study the role of SHP2 in 
both a drug sensitive and resistant context.  
We treated both cell lines with WZ4002 to determine the signaling changes caused 
by EGFR inhibition. Since SHP2 lies downstream of EGFR and promotes its signaling 
activity, SHP2 inhibition is predicted to show similar changes to those caused by EGFR 
inhibition. After 24 hours treatment we detected an increase in p27 and a significant 
decrease in pErk1/2, pSrc, pAkt, and c-Myc levels by immunoblot (Fig. 8A). WZ4002 
activity was confirmed by checking the phosphorylation levels of EGFR. Treatment 
resulted in complete dephosphorylation of the activating Y1080 site of EGFR (Fig. 8B).  
We previously described the novel SHP2 inhibitor SPI-112me. This compound binds 
the PTP catalytic domain leading to decreased Ras/MAPK signaling and enhanced 
STAT1 phosphorylation upon IFNγ stimulation [154]. To determine the effect of SHP2 
inhibition on cell viability, we treated HCC827 and H1975 cells with SPI-112me for 6 
days. We observed decreased proliferation in both cell lines (Fig. 9). SPI-112me 
treatment for 24 hours reduced pErk1/2 levels in both cell lines and pSrc levels in 
HCC827 cells, though no major changes were detected in pAkt and pSrc levels (Fig. 
10). Since SHP2 inhibition may increase EGFR mediated PI3K pathway activation, we 
did not expect to see a decrease in Akt activity in our cells [49, 50]. On the other hand, 
while SHP2 is involved in EGFR mediated Src activation; it is possible that in H1975 
cells GOF EGFR mutant can activate Src through an alternative pathway, thus SHP2 
inhibition would not result in lowered pSrc levels.                                                       
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Figure 8. WZ4002 treatment decreases cell signaling and pEGFR levels. HCC827 and 
H1975 cells were plated in 6 well plates and grown to confluence in complete medium 
then serum starved for 16 hours. Cells were treated with indicated concentrations of 
WZ4002 in complete medium for 24 hours followed by protein extraction. (A) 
Immunoblot was performed with indicated antibodies after 10% SDS-polyacrylamide gel 
separation. (B) 1mg protein from cleared lysate was immuno-precipitated using EGFR 
antibody and Protein-A agarose beads. Immunoblot was performed with indicated 
antibodies. 
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Figure 9. SPI-112me treatment decreases cell proliferation. HCC827 and H1975 cells 
were plated in 96 well plates (1000 cells/well), rested overnight, then treated with 
indicated SPI-112me concentrations for 6 days in complete medium. Cell proliferation 
was assayed using the CellTiter-Glo reagent. Graph values represent an average of 
four independent experiments. 
 
 
 
Figure 10. SPI-112me treatment decreases pErk1/2 levels.  HCC827 and H1975 cells 
were plated in 6 well plates (200,000 cells/well) and rested overnight in complete 
medium. After 16 hours serum starvation, cells were treated with indicated SPI-112me 
concentrations in complete medium for 24 hours followed by protein extraction. 
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Immunoblot was performed with indicated antibodies following 10% SDS-
polyacrylamide gel separation. 
 
 
2.4.2 SHP2 knock-down by shRNA decreases cell proliferation and signaling 
To confirm that SHP2 inhibition can decrease GOF EGFR mutant mediated cell 
proliferation and signaling, we generated two HCC827 cell lines which stably express 
either the SHP2 shRNA construct 1049 or 3469 upon Dox induction. SHP2 knock-down 
in HCC827/1049 and HCC827/3469 cells resulted in a significant decrease in cell 
viability and soft agar colony formation compared to uninduced controls (Fig 11A, B). 
To determine whether SHP2 can specifically inhibit EGF induced cell growth, we 
serum starved HCC827/1049 cells for 72 hours then stimulated cells with EGF for an 
additional 72 hours. Cell proliferation was  significantly lower than controls (Fig. 11C) 
indicating SHP2 knock-down can specifically decrease EGFR mediated cell proliferation 
upon EGF stimulation. The decrease in cell viability seen in HCC827/1049 and 
HCC827/3469 cells is correlated with reduced levels of pErk1/2 and c-Myc caused by 
SHP2 knock-down (Fig. 11D). Similar results were not obtained in H1975 cells because 
the efficiency of SHP2 knock-down was poor, and no signaling changes or decrease in 
cell proliferation were detectable following Dox induction (data not included). 
 
2.4.3 SHP2 knock-down by siRNA decreases cell proliferation and signaling 
To confirm the results obtained in the previous section using HCC827/1049 and 
HCC827/3469 cells and to check whether SHP2 knock-down can overcome GOF EGFR 
mutant signaling in the drug resistant H1975 cell line we used a siRNA approach. SHP2 
targeted siRNA transfection efficiently knocked-down SHP2 levels in both cell lines, and 
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led to a significant decrease in cell proliferation and levels of pErk1/2 and c-Myc. 
Transfection of both cell lines using a non-silencing control siRNA did not cause any 
visible changes. (Fig. 12A, B).  
 
Figure 11. SHP2 knock-down by shRNA decreases cell proliferation and signaling. (A) 
HCC827/1049 and HCC827/3469 cells were plated in 96 well plates and grown for 6 
days in complete medium with or without 2µg/mL doxycycline. Cell proliferation was 
assayed using the CellTiter-Glo reagent. Graph values represent an average of four 
independent experiments. (B) After plating in 0.4% agar in six well plates, 
HCC827/1049 and HCC827/3469 cells were grown for 21 days with or without 2µg/mL 
doxycycline. Colonies were stained with MTT and counted manually. (C) HCC827/1049 
cells were plated in 96 well plates and grown for 3 days in complete medium with or 
without 2µg/mL doxycycline. 10ng or 20ng EGF was added at day 3 in serum free 
medium. Cell proliferation was assayed 3 days later using the CellTiter-Glo reagent. (D) 
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HCC827/1049 and HCC827/3469 cells were plated in 6 well plates (50,000 cells/well) 
and grown for 6 days in complete medium with or without 2µg/mL doxycycline followed 
by protein extraction. Immunoblot was performed with indicated antibodies following 
10% SDS-polyacrylamide gel separation. ( * = p<.0001 as measured using Mann-
Whitney test) 
 
 
 
Figure 12. SHP2 knock-down by siRNA decreases cell proliferation and signaling. (A) 
HCC827 and H1975 cells were plated in 96 well plates (1000 cells/well) and rested 
overnight. Cells were transfected with 25nM non-silencing or SHP2 siRNA in 100µL 
Optimem and .5 µL Lipofectamine 2000 for 6 hours. Cells were then grown for 72 hours 
in complete medium. Cell proliferation was assayed using the CellTiter-Glo reagent. 
Graph values represent an average of two independent experiments (B) HCC827 and 
H1975 cells were plated in 12 well plates (20,000 cells/well) and rested overnight. Cells 
were transfected with 25nM non-silencing or SHP2 siRNA for 6 hours in 700µL 
Optimem with 2µL Lipofectamine 2000. Optimem was removed after transfection and 
cells were grown for 72 hours in complete medium then serum starved for 16 hours 
prior to protein extraction. Immunoblot was performed with indicated antibodies after 
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10% SDS-polyacrylamide gel separation. (P - parental, NS - non-silencing) (* = p<.0001 
as measured using Mann-Whitney test) 
 
 
2.4.4 Expression of a dominant negative SHP2 mutant decreases cell proliferation and  
signaling  
Previous work has shown that different domains of SHP2 play distinct regulatory 
functions [155]. The previous siRNA and shRNA knock-down experiments describe an 
important role for SHP2 in GOF EGFR mutant mediated signal transduction, but the 
drawback of this approach is the removal of the entire SHP2 protein. In that case, it is 
unclear whether the changes seen are caused by absence of the PTP catalytic function 
or by a secondary function of SHP2. To address this issue, we generated HCC827 cells 
that stably express the dominant negative SHP2 mutant SHP2CSDA. The PTP domain of 
this mutant is catalytically inactive while the rest of the protein is intact. When expressed 
in cells, SHP2CSDA competes with endogenous wild type SHP2 for substrate binding and 
decreases the positive regulatory effects of SHP2 [156]. SHP2CSDA expression in 
HCC827 cells caused a small but significant decrease in cell proliferation and levels of 
pErk1/2 (Fig. 13A, B). The mild effect of SHP2CSDA on cell viability is most likely caused 
by failure of the SHP2 mutant to fully out-compete endogenous SHP2 for substrate 
binding. Indeed, despite three rounds of cell sorting HCC827 cells still only expressed 
small amounts of the dominant negative SHP2CSDA mutant (Fig. 13B). These results do 
confirm though that intact PTP catalytic function is required to promote GOF EGFR 
mutant signal transduction and that the changes in cell signaling are most likely not 
caused by a secondary function of SHP2. 
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Figure 13. Expression of a dominant negative SHP2 mutant decreases cell proliferation 
and signaling. (A) HCC827 cells were plated in 96 well plates (1000 cells/well) and 
grown in complete medium for 6 days. Cell proliferation was assayed using the 
CellTiter-Glo reagent. Graph values represent an average of four independent 
experiments (B) HCC827 cells were plated in 6 well plates (200,000 cells/well) and 
grown in complete medium for 48 hours before protein extraction. Immunoblot was 
performed with indicated antibodies following 10% SDS-polyacrylamide gel separation. 
(P - Parental, EV - empty vector, CSDA - SHP2CSDA) ( * = p<.002 as measured using 
Mann-Whitney test) 
 
 
2.4.5 Characterization of the Dox inducible CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA  
transgenic mouse model 
After concluding our in vitro studies, it became evident that SHP2 activity is indeed 
required for cell survival and growth of GOF EGFR mutant dependent lung cancer cell 
lines, regardless of T790M mutation presence. SHP2 inactivation by knock-down, 
inhibition, or dominant negative SHP2 mutant expression significantly reduced cell 
proliferation and activation of the Ras/MAPK pathway. To verify these results and test 
whether targeting SHP2 is relevant to GOF EGFR mutant driven lung cancer in vivo, we 
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generated a novel tetO-SHP2CSDA Dox inducible transgenic mouse model which 
expresses the SHP2CSDA mutant under the control of the tetO promoter (Fig. 14A). 
 
Figure 14. PCR analysis to identify tetO-SHP2CSDA founder lines. (A) The tetO-
SHP2CSDA construct contains 2 chicken beta globin insulators upstream of the tetO 
promoter and a mouse protamine 1 poly-adenylation tail. The tetO-EGFRL858R construct 
expresses the GOF EGFRL858R mutant under the control of the tetO promoter. The 
CCSP-rtTA construct directs expression of the reverse tetracycline transactivator in type 
II pneumocytes under the control of the Clara cell secretory protein promoter. (B) PCR 
analysis using DNA extracted from tail snips to identify positive founder lines. 
 
Transgenic mice were obtained by microinjecting the DNA fragment containing the 
tetO-SHP2CSDA cassette into zygotes from FVB/N mice and growing the embryos in 
pseudo-pregnant CD-1 mice. After two rounds of DNA microinjection, we obtained nine 
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founder lines (Line 61, 65, 669, 674, 676, 374, 382, 389, and 390) exhibiting germline 
transmission of the transgene (Fig. 14B). Unfortunately, line 61, 65, 674, 374, 382, and 
390 displayed leaky transgene expression at the mRNA and protein levels in lung tissue 
(Fig. 15). Based on these results, we selected line 669 and line 65 for further study. 
 
Figure 15. Founder line leaky expression check. Lungs were collected from wild type 
and monotransgenic tetO-SHP2CSDA mice and snap frozen in liquid nitrogen. Total lung 
tissue was split in two. Half was used for RNA extraction, half for protein extraction. RT-
PCR was performed according to protocol. SHP2CSDA was immunoprecipitated using 
Flag tag antibody and Protein-G agarose beads. Immunoblot was performed using Flag 
antibody following 10% SDS-polyacrylamide gel separation. 
 
We bred bitransgenic CCSP-rtTA/tetO-SHP2CSDA mice to direct expression of the 
transgene to lung epithelial cells (abbreviated C/65 and C/669). After one month of Dox 
induction, SHP2CSDA expression was almost tripled in the lungs of C/65 mice and was 
also detectable in the lungs of C/669 mice (Fig. 16). We decided to include line 65 
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despite its leakiness (Fig. 17A) because of its high expression of the SHP2CSDA 
transgene (Fig. 17B). Line 669 does not exhibit leaky expression (Fig. 17A) but 
transgene expression is low (Fig. 17B), so it might have a more moderate effect on 
GOF EGFR mutant signaling. 
 
Figure 16. Dox induction triggers SHP2CSDA expression in the lungs of bitransgenic 
CCSP-rtTA/tetO-SHP2CSDA mice. Lungs were collected from Dox induced/uninduced 
bitransgenic and wild type mice and snap frozen in liquid nitrogen. Total lung tissue was 
split in two. Half was used for RNA extraction, half for protein extraction. RT-PCR was 
performed according to protocol. SHP2CSDA was immunoprecipitated using Flag tag 
antibody and Protein-G agarose beads. Immunoblot was performed using Flag antibody 
following 10% SDS-polyacrylamide gel separation. (WT - wild type, B - bitransgenic 
CCSP-rtTA/tetO-SHP2CSDA) 
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Figure 17. Comparison of SHP2CSDA transgene levels and leaky expression between 
founder line 669 and 65. (A) Multiple organs were collected from monotransgenic tetO-
SHP2CSDA mice from line 65 or 669. RNA was extracted using Trizol and RT-PCR 
performed according to protocol. (B) SHP2CSDA transgene levels of founder line 65 and 
669 were checked at the DNA level using slot-blot hybridization. Founder lines lacking 
the SHP2CSDA transgene were used as negative controls. (Br - Brain, Lu - Lung, Li - 
Liver, Sp - Spleen, Ki - Kidney, In - Intestine, Co - Colon) 
 
We also obtained an additional transgenic mouse line which expresses the 
EGFRL858R mutant under the control of the tetO promoter (Fig. 14A). When Dox is 
administered to CCSP-rtTA/tetO-EGFRL858R bitransgenic mice, the GOF EGFR mutant 
is expressed in type II lung pneumocytes and induces epithelial cell transformation. 
Within a few weeks of Dox induction, the mice develop diffuse hyperproliferative lesions 
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which progress to a more aggressive phenotype with the formation of multifocal 
adenomas. Dox withdrawal results in tumor regression, highlighting a dependence on 
sustained EGFRL858R expression for tumor survival [140]. We bred our bitransgenic mice 
to the EGFRL858R mice to generate tritransgenic CCSP-rtTA/tetO-EGFRL858R/tetO-
SHP2CSDA mice (abbreviated C/EGFR/65 for founder line 65 and C/EGFR/669 for 
founder line 669). Dox induction triggered expression of both transgenes in the lungs of 
tritransgenic mice (Fig. 18).  
 
Figure 18. Dox induction triggers SHP2CSDA and EGFRL858R expression in the lungs of 
tritransgenic CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice. Lungs were collected 
from tritransgenic mice after 0, 2 and 4 weeks of Dox induction. Total lung tissue was 
split in two. Half was used for RNA extraction, half for protein extraction. RT-PCR was 
performed according to protocol. SHP2CSDA was immunoprecipitated using Flag tag 
antibody and Protein-G agarose beads. Immunoblot was performed using indicated 
antibodies following 10% SDS-polyacrylamide gel separation.  
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2.4.6 SHP2CSDA expression counters EGFRL858R mediated kinase activation  
After characterization of our transgenic mouse models, we fed CCSP-rtTA/tetO-
EGFRL858R/tetO-SHP2CSDA, CCSP-rtTA/tetO-EGFRL858R, and wild type mice Dox diet for 
4, 6, and 8 weeks. EGFRL858R expression increased Erk1/2 and Src activity as indicated 
by higher levels of pErk1/2 T202/Y204 and pSrc Y416 in the lungs of bitransgenic mice 
compared to wild type controls (Fig. 19). As expected, SHP2CSDA expression countered 
the EGFR mutant induced pErk1/2 increase. Interestingly, the SHP2 mutant also 
reduced pSrc levels in both tritransgenic line and pAkt levels in C/EGFR/669 mice (Fig 
19). It is possible that expression of the SHP2CSDA mutant is higher in the lungs of 
tritransgenic mice than in our HCC827/SHP2CSDA cell culture model, and can better out-
compete endogenous SHP2 for substrate binding resulting in a stronger impact on 
EGFRL858R mediated signal transduction.  
 
2.4.7 SHP2CSDA expression decreases EGFRL858R mediated tumor onset, progression  
and burden 
As described earlier, bitransgenic CCSP-rtTA/tetO-EGFRL858R mice develop a 
diffuse form of adenocarcinoma within four weeks of Dox induction. At later time points, 
the disease progresses to a more aggressive phenotype and mice develop multifocal 
adenomas. Dox induced SHP2CSDA expression in tritransgenic CCSP-rtTA/tetO-
EGFRL858R/tetO-SHP2CSDA mice still triggered cellular transformation, but tumor areas 
were smaller and more restricted compared to bitransgenic controls (Fig. 20A). 
Moreover, SHP2CSDA expression seemed to prevent progression of the disease to a 
more aggressive phenotype since few adenomas were detected (Fig. 20A).  
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Figure 19. Signaling changes caused by SHP2CSDA expression in CCSP-rtTA/tetO-
EGFRL858R/tetO-SHP2CSDA mice. Lungs were collected and snap frozen in liquid 
nitrogen from wild type, bitransgenic CCSP-rtTA/tetO-EGFRL858R, and tritransgenic 
CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice after 4, 6, and 8 weeks of Dox 
induction. Immunoblot was performed using indicated antibodies following 10% SDS-
polyacrylamide gel separation.  
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To compare tumor burden in bitransgenic versus tritransgenic animals, we 
collaborated with the Moffitt Cancer Center Microscopy Core to design a computer 
algorithm that objectively quantifies the percentage of healthy epithelial cells and tumors 
cells in lungs using H&E slides. The software was trained to differentiate between 
different cell types to calculate the percentage of tumor cells in the mouse lungs. The 
results of the analysis are an average of three H&E slides per animal representing 
about half of the total lung volume. SHP2CSDA expression significantly decreased tumor 
burden in C/EGFR/65 and C/EGFR/669 mice starting at week 4 of Dox induction 
compared to C/EGFR mice (Fig. 20B, Table 1). These results confirm that SHP2 also 
plays an important role in mediating the tumorigenic activity of the GOF EGFRL858R 
mutant in vivo, and reinforce the validity of SHP2 as a potential therapeutic target in 
GOF EGFR mutant dependent lung cancer. 
 
Table 1. P-values for tumor burden of tritransgenic mice compared to bitransgenic mice 
Time 
point Line n p-value 
Time 
point Line n p-value 
C/EGFR 5   C/EGFR 7   
C/EGFR/65 4 0.6889 C/EGFR/65 10 0.0001 Week 2 
C/EGFR/669 5 0.1767 
Week 6 
C/EGFR/669 6 0.0001 
C/EGFR 5   C/EGFR 11   
C/EGFR/65 5 0.0034 C/EGFR/65 10 0.0003 Week 4 
C/EGFR/669 6 0.0007 
Week 8 
C/EGFR/669 10 0.0024 
 
P-values were calculated using an unpaired parametric t-test with Welch’s correction 
comparing results of either C/EGFR/65 mice to C/EGFR mice or C/EGFR/669 mice to 
C/EGFR mice for each time point. 
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Figure 20. SHP2CSDA expression decreases EGFRL858R mediated tumorigenesis. (A) 
Lungs were collected from wild type, CCSP-rtTA/tetO-EGFRL858R, and CCSP-rtTA/teO-
EGFRL858R/tetO-SHP2CSDA mice, flushed with PBS then insufflated and fixed overnight in 
10% buffered formalin. Lungs were processed by the Moffitt Cancer Center Histology 
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Core. (B) Three H&E slides per mice were scanned using the Aperio™ ScanScope XT 
and analyzed using a custom algorithm designed using the Genie® v1 histology pattern 
recognition software by the Moffitt Cancer Center Microscopy Core. 
 
 
2.4.8 GOF EGFR mutations induce Gab1 phosphorylation and association with SHP2 
After establishing the importance of SHP2 in GOF EGFR mutant dependent lung 
cancer, we next investigated how SHP2CSDA decreases tumor burden and signaling in 
CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice. We performed a mass spectrometry 
analysis to determine the binding partners of SHP2CSDA in the lungs of tritransgenic 
mice (Fig. 21, Table 2). One of the top candidates was Gab1, which is a well known 
binding partner of SHP2 [34, 35].  
 
Figure 21. Mass Spectrometry analysis of SHP2CSDA binding partners in the lungs of 
CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice. Protein was extracted from the lungs 
of three CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice and combined in one sample. 
10mg protein was immunoprecipitated using Flag antibody and Protein-G agarose 
beads. Immunoblot was performed using PY20 antibody following 10% SDS-
polyacrylamide gel separation. Gel slices corresponding to phosphorylated bands on 
immunoblot were cut out and analyzed by mass spectrometry. 
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Table 2. SHP2CSDA bound proteins identified by mass spectrometry. 
 
 
 
 
 
  
 
 
57 
Table 2. Continued 
 
Table contains top candidates with a minimum of 3 matching peptides. Protein 
identification by mass spectrometry was performed by the Moffitt Cancer Center 
Proteomics Core. Tryptic peptides from gel slides were analyzed with a nanoflow liquid 
chromatograph coupled to an electrospray ion trap mass spectrometer for tandem mass 
spectrometry peptide sequencing. Five tandem mass spectra were collected in a data-
dependent manner following each survey scan. Sequences were assigned using 
Mascot (www.matrixscience.com) searches against mouse entries. (M.W.-Molecular 
weight is an approximation, not exact value) 
 
To assess the role of Gab1 in GOF EGFR mutant dependent lung cancer, we 
started by checking its phosphorylation status in our HCC827 and H1975 cells and 
found that Gab1 is indeed phosphorylated in these cell lines (Fig. 22A). We then treated 
both HCC827 and H1975 cells with Erlotinib. In HCC827 cells, EGFR inhibition resulted 
in decreased levels of pGab1, concurrent with a dissociation of the Gab1/SHP2 
complex (Fig. 22A). These results indicate that SHP2/Gab1 association is directly 
promoted by GOF EGFR mutant signaling. Since H1975 cells express the drug resistant 
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T790M mutation, Erlotinib treatment should have no effect on these cells. As expected, 
Erlotinib treatment of H1975 cells did not affect Gab1/SHP2 association and only 
slightly decreased Gab1 phosphorylation at the highest concentration (Fig. 22A).  
 
Figure 22. GOF EGFR mutant mediated Gab1 phosphorylation and Gab1/SHP2 
association is disrupted by EGFR inhibition in EGFR dependent lung cancer cell lines. 
(A) HCC827 and H1975 cells were plated in 10cm plates in complete medium and 
grown to near confluence. Cells were treated with indicated concentration of Erlotinib for 
24 hours before protein extraction. Immunoprecipitation was done using 1mg protein, 
Gab1 antibody and Protein-G agarose beads. Immunoblot was performed using 
indicated antibodies following 10% SDS-polyacrylamide gel separation. IP-IB and 
western blot data was obtained from the same cell lysate per sample. (B) The same 
procedure described in (A) was used, except cells were treated with WZ4002 instead. 
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To further confirm our results, we then treated both cell lines with the EGFR inhibitor 
WZ4002 which overcomes the drug resistant T790M mutation. In this case, both cell 
lines showed a significant decrease in pGab1 levels and association of Gab1 and SHP2 
(Fig. 22B). These results indicate GOF EGFR mutant phosphorylates Gab1 then 
recruits and activated SHP2 which in turn positively regulates EGFR signal 
transduction. 
Based on our in vitro results we wondered whether a similar pattern of SHP2 
activation takes place in our bitransgenic CCSP-rtTA/tetO-EGFRL858R mice. We 
detected increased levels of pGab1 and Gab1/SHP2 association in C/EGFR mice 
compared to wild type controls (Fig 23). Interestingly, SHP2CSDA expression in 
C/EGFR/65 and C/EGFR/669 mice significantly decreased pGab1 levels leading to 
dissociation of the Gab1/SHP2 complex (Fig 23), potentially revealing the mechanism 
by which SHP2CSDA decreases GOF EGFR mutant mediated Ras/MAPK and Src 
pathway activation. 
 
Figure 23. EGFRL858R mediated Gab1 phosphorylation and Gab1/SHP2 association is 
disrupted by SHP2CSDA expression in the lungs of tritransgenic mice. Protein was 
extracted from mouse lungs. Immunoprecipitation was performed using 1mg protein, 
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Gab1 antibody and Protein-G agarose beads. Immunoblot was performed using 
indicated antibodies following 10% SDS-polyacrylamide gel separation. IP-IB and 
western blot data was obtained using the same cell lysate per sample. (WT - wild type, 
B - bitransgenic CCSP-rtTA/tetO-EGFRL858R, 669 - C/EGFR/669, 65 - C/EGFR/65) 
 
 
2.5 Discussion  
The EGFR oncogene is a well described driver of lung tumorigenesis and an 
established therapeutic target in a molecularly defined subset of NSCLC [157]. Multiple 
successful approaches have been developed to target GOF EGFR mutants including 
small tyrosine kinase inhibitors and monoclonal antibodies [158, 159]. Unfortunately, the 
majority of patients relapse, and develop tumors that no longer respond to EGFR 
tyrosine kinase inhibition [160]. Drug resistance is achieved by lung cancer cells through 
multiple mechanisms including the acquisition of secondary EGFR mutations, c-Met 
amplifications, and others [120-123]. While second and third generation tyrosine kinase 
inhibitors are being developed, it is obvious that solely targeting EGFR is not sufficient 
to treat patients with recurrent tumors [67, 124]. These observations highlight an urgent 
need for the identification of additional therapeutic targets for the treatment of GOF 
EGFR mutant NSCLC patients. 
Previous work has shown that SHP2 is a key downstream effector of EGFR signal 
transduction [34, 57]. EGFR activation recruits SHP2 to the cell membrane where it 
becomes activated and positively regulates the Ras/MAPK and Src signaling pathways 
through multiple mechanisms [36, 42, 44]. The importance of SHP2 in EGFR signal 
transduction led us to inquire whether SHP2 is also required by GOF EGFR mutants 
and could potentially serve as a therapeutic target in GOF EGFR mutant dependent 
NSCLC. 
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To determine whether targeting SHP2 impacts cell proliferation and survival in both 
a drug sensitive or resistant context, we selected the HCC827 and H1975 lung cancer 
cell lines for our experiments. HCC827 cells respond to EGFR inhibition while H1975 
cells carry the gatekeeper mutation T790M and are resistant to Erlotinib. SHP2 
inhibition using the SPI-112me inhibitor decreased cell proliferation and pErk1/2 levels. 
Similarly, SHP2 knock-down using shRNA or siRNA also decreased cell viability, colony 
formation, and Ras/MAPK signaling in both GOF EGFR mutant dependent lung cancer 
cell lines. These results demonstrate that SHP2 function is required to mediate cell 
signaling and demonstrate a key role for SHP2 in cell growth of both drug resistant and 
sensitive lung cancer cells. To check whether intact SHP2 PTP catalytic activity is 
necessary to mediate GOF EGFR mutant signal transduction, I expressed the dominant 
negative SHP2CSDA mutant in HCC827 cells and observed a decrease in cell 
proliferation and Erk1/2 activation. This data indicate that intact PTP catalytic function is 
indeed required to mediate GOF EGFR mutant signaling.  
In the next step of our study, we decided to test our hypothesis in vivo. We 
generated a novel Dox inducible tetO-SHP2CSDA transgenic mouse model which 
expresses the dominant negative SHP2CSDA mutant under the control of the tetO 
promoter in lung epithelial cells. We also obtained a second transgenic mouse model 
that expresses the EGFRL858R mutant under the control of the tetO promoter. We then 
bred bitransgenic CCSP-rtTA/tetO-EGFRL858R and tritransgenic CCSP-rtTA/tetO-
EGFRL858R/tetO-SHP2CSDA mice to study the effects of the SHP2CSDA mutant in an 
EGFRL858R driven mouse model of lung carcinogenesis. Dox induction of bitransgenic 
mice increased pErk1/2 and pSrc levels compared to wild-type controls. SHP2CSDA 
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expression countered EGFRL858R mediated kinase activation and significantly reduced 
tumor formation and burden in the lungs of tritransgenic mice. The dominant negative 
SHP2CSDA mutant also conferred a protective effect by blocking progression of the 
disease to a more aggressive phenotype. These results demonstrate that targeting 
SHP2 can significantly impact GOF EGFR mutant dependent lung tumorigenesis and 
support the validity of SHP2 as a therapeutic target for GOF EGFR mutant dependent 
NSCLC.  
We performed a mass spectrometry analysis to identify the binding partners of 
SHP2CSDA in the lungs of tritransgenic CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice 
and determine how SHP2CSDA can decrease cell signaling and tumor growth. The 
results of the analysis identified Gab1 as a top candidate. Gab1 is the main docking 
protein for SHP2, and association between the two is required for proper SHP2 
activation and function [35]. Using our lung cancer cell lines, we determined that EGFR 
inhibition decreases Gab1 phosphorylation and disrupts Gab1/SHP2 association.  
In our bitransgenic CCSP-rtTA/tetO-EGFRL858R mouse model, we found that EGFRL858R 
increases pGab1 levels and Gab1/SHP2 complex formation in the lungs. SHP2CSDA 
expression significantly decreases Gab1 phosphorylation and Gab1/SHP2 association. 
A possible explanation for this observation is that SHP2 can regulate the activity of its 
own docking protein [35, 60]. When SHP2CSDA binds to pGab1, it prevents the activation 
of a positive feedback loop and blocks the phosphorylation of additional Gab1 proteins, 
thus disrupting Gab1/SHP2WT complex formation and causing the decreases in cell 
signaling seen in tritransgenic CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice (Fig. 
24).  
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Figure 24. SHP2CSDA mechanism of action in CCSP-rtTA/tetO-EGFRL858R/tetO-
SHP2CSDA mice. GOF EGFRL858R phosphorylates Gab1 and recruits SHP2CSDA which 
prevents phosphorylation of additional Gab1 proteins and blocks recruitment of wild 
type SHP2 and activation of the Ras/MAPK and Src signaling pathways. 
 
 
 In conclusion, we have described an important function of SHP2 as a key mediator 
of GOF EGFR mutant driven lung tumorigenesis and established SHP2 as a potential 
therapeutic target for the treatment of GOF EGFR mutant dependent NSCLC.  
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Chapter 3: Active SHP2 mutant induces lung hyperproliferative lesions and 
adenoma in transgenic mice 
 
3.1 Abstract  
SHP2 plays an important role in carcinogenesis. Gain of function SHP2 mutants are 
known leukemic oncogenes and have been identified in multiple cancer types, including 
lung cancer. However, the oncogenic potential of activating SHP2 mutants in lung 
tumorigenesis has not been established. To address this question we generated Dox 
inducible bitransgenic CCSP-rtTA/tetO-SHP2E76K mice that express the GOF SHP2E76K 
mutant in lung epithelial cells under the control of a rat Clara cell secretory protein 
promoter fragment. SHP2E76K expression increased pErk1/2, pSrc, c-Myc and Mdm2 
levels in the lungs of bitransgenic mice. After 6 to 9 months of Dox induction, 
bitransgenic CCSP-rtTA/tetO-SHP2E76K mice developed atypical adenomatous 
hyperplasia that progressed to adenoma and adenocarcinoma in the lungs. These 
results demonstrate a new role for this GOF SHP2 mutant as a lung cancer oncogene. 
To determine whether tumor survival is dependent on continued SHP2E76K expression, 
we analyzed tumor-bearing mice after 1 month of Dox withdrawal by Magnetic 
Resonance Imaging (MRI). The results of the MRI analysis indicate that SHP2E76K 
expression is required for tumor maintenance in this mouse model of lung 
adenocarcinoma. Further study revealed that SHP2E76K expression increased Gab1 
phosphorylation and promoted Gab1/SHP2 complex formation in the lungs of 
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bitransgenic mice and cancer cell lines. This data indicate that GOF SHP2 mutants 
auto-regulate the tyrosine phosphorylation of their own docking protein. Since inhibition 
of Src family kinases (SFKs) decreases pGab1 levels in cell lines expressing an 
activating SHP2 mutant, and SHP2E76K expression increases Src phosphorylation, it 
seems likely that the SFKs are an important mediator of this positive feedback loop 
mechanism. 
 
3.2 Introduction  
Protein tyrosine kinases have traditionally been identified as inducers of cell 
signaling and act as oncogenes when acquiring gain of function mutations [161]. Since 
protein tyrosine phosphatases usually counter the biochemical reaction of PTKs, they 
have generally been considered tumor suppressors. However, increasing evidence 
suggests that some PTPs collaborate with PTKs to promote cell signaling and 
transformation [162, 163]. Indeed, tyrosine phosphorylation does not always positively 
regulate the target protein. For example, phosphorylation of tyrosine sites such as Src 
Y530 or CDK1 Y15 negatively regulates enzyme activity of these kinases [14-16].  
On the other hand, phosphorylation of the p120RasGap and c-CBL tyrosine binding 
sites upon EGFR activation recruits these negative regulators to the cell membrane and 
terminates EGFR signaling [164-166]. In these circumstances, dephosphorylation of the 
p120RasGap and c-CBL docking sites and the inhibitory Src Y530 and CDK1 Y15 sites 
promotes PTK signal pathway activity. This concept of positive collaboration between 
PTKs and PTPs is exemplified by SHP2. 
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Indeed, growth factor receptors recruit and activate SHP2 by inducing a 
conformational change that relieves its auto-inhibitory mechanism. Active SHP2 
promotes Ras/MAPK and Src signaling pathway activation [26, 34, 45]. Because of its 
positive regulatory effects on cell signaling, SHP2 is a cancer essential gene in certain 
types of carcinoma and is required to maintain cell growth and survival [55, 57]. 
Moreover GOF SHP2 mutations are known leukemic oncogenes and have been 
identified in approximately 35% of juvenile myelomonocytic leukemia, 10% of childhood 
myelodysplastic syndromes, 7% of B-cell acute lymphoblastic leukemia, and 4% of 
acute myelogenous leukemia  [17, 167]. The majority of activating SHP2 mutations are 
located in the N-SH2/PTP interface and disrupt the auto-inhibitory mechanism, 
conferring constitutive activity to the PTP catalytic domain (Fig. 4) [58]. Activating SHP2 
mutations have also been identified in carcinoma at lower rates than in hematologic 
malignancies. According to the COSMIC database, as of 4-14-2014, about 1.81% of 
lung cancer cases carry GOF SHP2 mutations. Even though this percentage may seem 
small, it still represents a large number of people due to the high prevalence of lung 
cancer in the population. 
The American Cancer Society estimates there will be about 224,210 new cases of 
lung cancer in 2014, causing approximately 159,260 deaths (about 27% of all cancer 
deaths). Lung cancer is usually initiated by activation of a single oncogene. Kras, 
EGFR, and Alk are the most common drivers of lung tumorigenesis [147, 148]. 
Additional oncogenes such as RIT1 and RET fusions have been identified in a smaller 
percentages of cases [168-170]. These genes provide interesting targets for the 
development of new drugs that can broaden treatment opportunities for patients. Since 
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GOF SHP2 mutations are present in lung cancer, the contribution of SHP2 to 
tumorigenesis merits further investigation. 
To achieve this goal, we generated a novel Dox inducible mouse model that carries 
the GOF SHP2E76K mutant (tetO-SHP2E76K). We bred these mice to a second strain of 
transgenic mice which express rtTA under the control of the Clara cell secretory protein 
to direct expression of SHP2E76K in type II pneumocytes [131]. The CCSP-rtTA mouse 
model has previously been validated as a reliable model of NSCLC [131].  
 
3.3 Material and methods  
3.3.1 Transgenic mice  
3.3.1.1 Transgene microinjection 
The L3/L2-tetO vector was constructed as described in the previous section. The 
DNA fragment containing the human SHP2E76K mutant was excised from a pCDNA3.1 
vector and subcloned into the EcoRV site between the tetO and polyA sequences of 
L3/L2-tetO plasmid [62]. The completed SHP2E76K transgene was excised from the 
vector by digestion with BssHII and isolated by agarose gel electrophoresis followed by 
EluTrap electroelution and EluTip purification. Ethanol precipitated DNA was 
resuspended in sterile microinjection buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 7.5) 
and microinjected at 3 ng/ µl into 0.5 dpc fertilized FVB/N zygotes per standard 
methods. Zygotes were then surgically implanted into the oviducts of 0.5 dpc 
pseudopregnant CD-1 females. Offspring were tail biopsied at weaning and genotyped 
by PCR and slot blot hybridization to identify transgenic lines. This work was performed 
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by Dr. Liwei Chen and Dr. Wu from the Wu laboratory and the Moffitt Cancer Center 
Transgenic Mouse Model Core. 
 
3.3.1.2 Genotyping of tetO-SHP2E76K transgenic mice 
TetO-SHP2E76K mice were genotyped by PCR using the GoTaq® Hot Start Green 
Master Mix (Promega) and the following primers: SHP2T1, 5’- 
AGACGCCATCCACGCTGTTTTGAC-3’ and SHP2T2, 5'-
TCTCTTTTAATTGCCCGTGATGTT-3’. PCR reaction was performed in a total volume 
of 25 µL using the following conditions: 4 min denaturation at 94°C, 35 cycles of 94°C 
for 30 sec, 57°C for 30 sec, and 72°C for 30 sec wi th a final extension step of 72°C for 4 
min yielding a 430-bp PCR fragment. 
 
3.3.1.3 CCSP-rtTA transgenic mice 
CCSP-rtTA transgenic mice (in inbred FVB/N background) were provided by Dr. 
Jeffrey A. Whitsett. Animals were maintained in pathogen-free housing conditions. 
Rodent chow containing 200 mg/kg Dox (Dox diet, Bio-Serv) was used to activate the 
reverse tetracycline transactivator. Animal studies and care were approved by the 
Institutional Animal Care and Use Committee of the University of South Florida and 
followed institutional and national guidelines. 
 
3.3.2 RT-PCR analysis  
Tissue samples were snap frozen in liquid nitrogen. RNA was extracted using Trizol 
reagent (Life Technologies) according to manufacturer protocol. Samples were treated 
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with DNase I (Life Technologies) to avoid DNA contamination. RT-PCR was performed 
using the SuperScript One-Step RT-PCR Platinum Taq system (Life Technologies) with 
the following primers: SHP2F1: 5'-GGTTGGACAAGGGAATACGG-3’ and SHP2R2: 5'-
AGGGCTCTGATCTCCACTCG-3’. RT-PCR reaction was performed in a total volume of 
50 µL using the following conditions: 30 min cDNA synthesis at 55°C, 4 min 
denaturation at 94°C then 35 cycles of 94°C for 30 sec, 57°C for 30 sec, 72°C for 30 
sec with a final extension step of 72°C for 4 min y ielding a 462-bp fragment.  
 
3.3.3 Immunoblotting, immunoprecipitation, and mass spectrometry analysis 
Antibodies to SHP2, Erk1/2, phospho-Erk1/2, Gab1, Akt, c-Myc, and β -actin were 
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Flag (rabbit), pGab1 (Y627), 
Phospho-Akt, and phospho-Src antibodies were from Cell Signaling Technology 
(Danvers, MA). Src antibody was from Calbiochem (Billerica, MA) and M2 Flag antibody 
was from Sigma (St. Louis, MO). Antibodies to MDM2 (clone 2A9) and MDMX (clone 
8C6) were obtained from Dr. Jiandong Chen and generated as described previously 
[171, 172]. The p53 antibody was purchased from IMGENEX (San Diego, CA).  
Frozen tissues were crushed and lysed with lysis buffer (50 mM Tris-HCl, pH 7.5, 
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 25 mM NaF, 5 mM Na4P2O7, 1 mM 
dithiothreitol, 1 mM Na3VO4, 100 µg/ml of phenylmethylsulfonyl fluoride, 2 µg/ml 
leupeptin, 2 µg/ml aprotinin, and 1% Triton X-100). Equal amounts of proteins from 
cleared tissue lysate were separated by 10% SDS-polyacrylamide gels and transferred 
to nitrocellulose filters for immunoblotting. Flag-tagged SHP2 was immunoprecipitated 
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from cleared tissue lysate by using the Flag M2 antibody and Protein-G agarose. 
Immunoblotting was performed as described previously [62, 153]. 
Hel cells were provided by Dr. Ken Zuckerman and cultured and cell lysates 
prepared for immunoblotting or immunoprecipitation analyses similar to that described 
previously [62, 153]. Tyrosine kinase inhibitors were from LC Laboratories (Woburn, 
MA).  
Protein identification by mass spectrometry was performed by the Moffitt Cancer 
Center Proteomics Core using standard procedure. Essentially, tryptic peptides from gel 
slides were analyzed with a nanoflow liquid chromatograph coupled to an electrospray 
ion trap mass spectrometer for tandem mass spectrometry peptide sequencing. Five 
tandem mass spectra were collected in a data-dependent manner following each survey 
scan. Sequences were assigned using Mascot (www.matrixscience.com) searches 
against mouse or human entries. Results from Mascot were compiled in Scaffold. 
 
3.3.4 qRT-PCR 
qRT-PCR was performed using Power SYBR Green reagents (Applied Biosystems) 
and proprietary primers for 18s rRNA or Mdm2 exon 1-3 from IDT (San Jose, CA). 
Samples were assayed in triplicates whereas standards, no amplification controls, and 
no DNA controls were performed in duplicates. The ABI PRISM 7900HT Sequence 
Detection System from Applied Biosystems was used to run qPCR. Data was 
normalized using 18s rRNA as the internal control and analyzed using the SDS software 
version 2.3. 
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3.3.5 Histology and immunohistochemistry 
Mice were euthanized by CO2 asphyxiation followed by cervical dislocation. Lungs 
were flushed twice with 10 ml PBS and insufflated with 10% buffered formalin. After 
overnight fixation in 10% buffered formalin solution at room temperature, paraffin blocks 
were prepared by standard procedure by the Moffitt Cancer Center Tissue Core. 
Sections (4µm thick) were stained with hematoxylin and eosin (H&E) for histological 
examination. 
For IHC analysis of pErk1/2, slides were stained using a Ventana Discovery XT 
automated system (Ventana Medical Systems, Tucson). Slides were deparaffinized with 
EZ Prep solution (Ventana). Heat-induced antigen retrieval method was used in Cell 
Conditioning 1 (Ventana). A rabbit pErk1/2 antibody (#4376, Cell Signaling, Danvers, 
MA) was used at a 1:200 dilution in PSS diluent (Ventana) and incubated for 32 min. 
Anti-rabbit secondary antibody (Ventana) was used for 20 min. The detection system 
used was the Ventana OmniMap kit and slides were counterstained with Hematoxylin.  
All slides were scanned and uploaded as digital images using the Aperio™ (Vista, CA) 
ScanScope XT with a 20x/0.8NA objective lens at a rate of 5 minutes per slide via 
Basler tri-linear-array. Digital images were stored in the Moffitt Network Operations 
Center and accessible to study participants via the password protected Spectrum 
(Aperio) web-based interface. 
 
3.3.6 MRI analysis 
Mice were anesthetized with 2% isoflurane, restrained in a mouse cradle mounted 
on an insertion device and positioned within the RF coil of the magnet while 
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continuously receiving isoflurane. Respiratory function and temperature of the animals 
were monitored and controlled throughout the imaging session using the SAI system 
(Small Animal Instruments, Inc.). Temperature control of the animals was achieved by a 
variable temperature gas unit and set to maintain a body temperature of 37 ± 1°C. 
MRI was performed using a 7-T horizontal magnet (ASR 310, Agilent Technologies) 
equipped with nested 205/120/HDS gradient insert and a bore size of 310 mm. 
Temperature control of the imaging gradients was achieved by means of a water chiller 
(Neslab Waters) and maintained at 12°C for all acqu isitions. Using a 35-mm Litz-cage 
coil (Doty Scientific), coronal T2-weighted fast spin-echo (FSE, 3D) sequences were 
acquired with TE/TR = 64/1000 ms, Matrix = 256x128x16, field of view (FOV) 
=90x45x16 mm and slice thickness of 1 mm over 8.5 minutes. Tumor volumes and 
dimensions were quantified by manually drawn regions of interest (ROI) using VnmrJ 
(Agilent Technologies, Inc.). MRI was performed by the Moffitt Cancer Center Animal 
Imaging Core. 
In an initial pilot study, T2-weighted FSEMs sequences were acquired with TR = 954 
ms, ESP = 7.5 ms, ETL = 8 (eff. TE = 60 ms), FOV = 40 x 90 mm, Matrix = 128 x 256, 
15 slices at 1 mm thickness, 8 averages and fat suppression in 3.75 minutes.  
 
3.4 Results  
3.4.1 Generation of Dox inducible tetO-SHP2E76K transgenic mice 
We selected the SHP2E76K mutant for our transgenic mouse model because it is a 
well characterized leukemic oncogene, confers the highest PTP catalytic activity of 
known GOF SHP2 mutants, and has previously been identified in lung cancer patients 
  
 
 
73 
[62, 173]. This point mutation is located in the N-SH2 binding domain and disrupts the 
auto-inhibitory mechanism conferring constitutive catalytic activity to the PTP domain 
(Fig 25).  
 
Figure 25. Crystal structure of the GOF SHP2E76K mutation (PDB: 2SHP). This structure 
is missing the c-terminal tail but otherwise contains the C-SH2 binding domain (yellow), 
the N-SH2 binding domain (red) and the PTP catalytic domain (green). The blue residue 
highlights the location of the E76K point mutation which disrupts the auto-inhibitory 
mechanism. 
 
 
To generate our transgene, we modified the tetracycline inducible tet-op mp1 vector 
by inserting two chicken beta globin insulators upstream of the tetO promoter and 
flanking the cassette with a pair of oppositely oriented heterotypic L2 and L3 loxP sites 
[133, 152]. The L2/L3 transgenic vector system is capable of undergoing Cre-
recombinase mediated cassette exchange [133]. We then subcloned a C-terminal Flag 
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tagged human SHP2E76K coding sequence downstream of the tetO promoter of our 
L2/L3 vector to obtain the tetO-SHP2E76K transgenic construct (Fig. 26A). Transgenic 
mice were obtained by microinjecting the DNA fragment containing the tetO-SHP2E76K 
cassette into zygotes from FVB/N mice and growing the embryos in pseudo-pregnant 
CD-1 mice. We identified eight founder lines (Line 394, 398, 400, 404, 417, 422, 425, 
428) that displayed germline transmission of the transgene (Fig. 26B).  
 
 
Figure 26. Transgenic constructs and founder line identification. (A) The tetO-SHP2E76K 
construct contains 2 chicken beta globin insulators upstream of the tetO promoter and a 
mouse protamine 1 poly-adenylation tail. The CCSP-rtTA construct directs expression 
of the reverse tetracycline transactivator in type II pneumocytes under the control of the 
Clara cell secretory protein promoter. (B) PCR analysis using DNA extracted from tail 
snips to identify positive founder lines. 
 
We selected founder lines 400, 398, 417 and 425 for further investigation. Founder 
line 400 expressed leaky expression of the SHP2E76K transgene at the mRNA level in all 
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organs tested (Fig. 27). Based on these results, we selected lines 398, 417, and 425 
that displayed no leaky expression for further study (Fig. 27).  
 
Figure 27. Founder line leaky expression check. Lungs were collected from 
monotransgenic tetO-SHP2E76K mice and snap frozen in liquid nitrogen. Trizol was used 
for RNA extraction and RT-PCR was performed according to protocol. (Lu - lung, Li - 
liver, Ki - kidney, Co - colon) 
 
We bred bitransgenic CCSP-rtTA/tetO-SHP2E76K mice (abbreviated C/398, C/417, 
and C/425) and screened for Dox inducible expression of SHP2E76K in the lungs. After 
one month of Dox induction, SHP2E76K was readily detectable in the lungs of 
bitransgenic mice at the mRNA and protein level (Fig 28). 
 
3.4.2 SHP2E76K expression induces Ras/MAPK and Src signaling pathway activation 
After characterizing our transgenic mouse model, we determined the biochemical 
changes caused by SHP2E76K expression in the lungs of CCSP-rtTA/tetO-SHP2E76K 
mice.  SHP2E76K expression increased pErk1/2 T202/Y204 and pSrc Y416 levels but did 
not affect pAkt S473 in the lungs of bitransgenic mice compared to wild type controls 
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(Fig. 29). SHP2E76K expression also increased c-Myc levels in the lungs of bitransgenic 
mice (Fig. 29). C-Myc is an important promoter of cell proliferation and is a driver 
oncogene of lung cancer [153, 174].  
 
Figure 28. Dox induced SHP2E76K expression is detectable in the lungs of bitransgenic 
CCSP-rtTA/tetO-SHP2E76K mice. Lungs were collected from Dox induced bitransgenic 
and wild type mice and snap frozen in liquid nitrogen. Total lung tissue was split in two. 
Half was used for RNA extraction, half for protein extraction. RT-PCR was performed 
according to protocol. SHP2E76K was immunoprecipitated using Flag tag antibody and 
Protein-G agarose beads. Immunoblot was performed using Flag antibody following 
10% SDS-polyacrylamide gel separation.  
 
 
Previous work has shown that activation of the Ras/MAPK pathway upregulates 
Mdm2 which suppresses p53 activity [175]. Experiments performed by Dr. Yuan Ren in 
the Wu laboratory have consistently shown that SHP2E76K transformed TF-1 cells and 
increased Mdm2 while reducing p53 but did not have any effect on MDMX [60, 62]. 
Moreover, Ras/MAPK pathway inactivation by the Mek inhibitor U0126 restored Mdm2 
to non-transformed levels, indicating that SHP2E76K upregulates Mdm2 through 
activation of the Ras/MAPK pathway [60]. To determine whether a similar mechanism of 
Mdm2 upregulation is present in our bitransgenic CCSP-rtTA/tetO-SHP2E76K mice, we 
  
 
 
77 
measured Mdm2 mRNA level expression by qRT-PCR. Results showed that Mdm2 
mRNA levels are significantly higher in the lungs of bitransgenic mice (n=4) compared 
to wild type controls (n=4) (Fig. 30) 
 
Figure 29. Signaling changes caused by SHP2E76K expression in CCSP-rtTA/tetO-
SHP2E76K mice. Lungs were collected and snap frozen in liquid nitrogen from wild type, 
monotransgenic tetO-SHP2E76K, and bitransgenic CCSP-rtTA/tetO-SHP2E76K mice after 
1 month of Dox induction. Immunoblot was performed using indicated antibodies 
following 10% SDS-polyacrylamide gel separation. (WT - wild type, M - monotransgenic, 
B - bitransgenic) 
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Figure 30. qRT-PCR analysis of Mdm2 mRNA levels in the lungs of bitransgenic mice 
compared to wild type controls. Lungs were collected from wild type or CCSP-rtTA/tetO-
SHP2E76K mice and snap frozen in liquid nitrogen. RNA was extracted using Trizol 
according to manufacturer protocol. qRT-PCR was repeated two times. Lung samples 
from each animal was assayed in triplicates (n=4). Average Ct values were 27.5 for WT 
and 25.8 CCSP/E76K. Statistical analysis was performed using the non parametric 
Mann-Whitney test. 
 
 
3.4.3 SHP2E76K expression induces hyperplasia and adenoma formation in lung 
epithelial tissue 
SHP2E76K expression caused significant histological alterations in the lungs of 
CCSP-rtTA/tetO-SHP2E76K mice. After 6 months of Dox induction, the majority of 
animals displayed extensive atypical adenomatous hyperplasia (n=12) (Fig. 31A). 25% 
of bitransgenic mice (n=12) developed adenomas as well, including in one case as early 
as 2 months after Dox induction (Fig. 31A). At the 9 months time point, 86.7% of 
bitransgenic mice (n=15) developed adenomas that were larger in size and several 
animals developed adenocarcinomas (defined by a diameter of ≥5mm) (Fig. 31B) [176]. 
Histological evaluation by a pathologist indicated that tumors were of papillary, solid, or 
mixed subtypes (Table 3) with features resembling human NSCLC.  
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In comparison, none of our monotransgenic tetO-SHP2E76K or wild type control mice 
developed hyperplasia or adenoma after 6 months of Dox induction (WT, n= 6; E76K, 
n=7). At the 9 month time point, 2 control mice developed tumors with similar 
histological features to tumors identified in bitransgenic mice (one WT and one E76K), 
but they were significantly smaller in size (WT, n= 9; E76K, n=4) (Fig. 30B) At 12 
months of Dox induction, two control mice displayed tumors (one WT and one E76K), 
one of them had features similar to adenocarcinoma, the other to squamous cell 
carcinoma (WT, n= 12; E76K, n=12).  
Overall, Dox induced CCSP-rtTA/tetO-SHP2E76K mice developed lung tumors at a 
significantly higher rate than monotransgenic tetO-SHP2E76K, CCSP-rtTA, or wild type 
controls (Fig. 32) indicating that SHP2E76K promotes lung tumorigenesis with NSCLC 
features in this transgenic mouse model of lung cancer. 
 
3.4.4 Dox withdrawal induces lung tumor regression 
For the next step of our study, we took advantage of the reversible feature of our 
transgenic mouse model and the small animal imaging facilities at the Moffitt Cancer 
Center to determine whether constant SHP2E76K expression is required for tumor 
maintenance. We set up a small pilot study to determine whether MRI can be used to 
detect established tumors in the lung of bitransgenic mice (n=4). Tumor presence was 
verified by dissection following positive identification by MRI analysis (Fig. 33). The 
results of our pilot study established MRI as a valid technique to detect lung tumors in 
vivo. 
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Figure 31. Histological evaluation of lung hyperplasia and adenoma formation in CCSP-
rtTA/tetO-SHP2E76K mice. Lungs were collected from wild type and CCSP-rtTA/tetO-
SHP2E76K mice, insufflated with 10% neutral buffered formalin, fixed overnight, then 
processed by the Moffitt Cancer Center Histology Core. Slides were stained with H&E, 
and histological alterations were evaluated by a pathologist (A) Bitransgenic mice 
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developed hyperproliferative lesions and small adenomas after 6 months of Dox 
induction. (B) Bitransgenic mice developed lung adenomas and adenocarcinomas after 
9 months of Dox induction. Only two mice out of 24 control animals developed 
adenomas after 9 months of Dox induction. 
 
 
Table 3. Histological evaluation of tumor subtype. 
 
H&E stained slides from representative lung tumor-carrying CCSP-rtTA/tetO-SHP2E76K 
and control mice were evaluated by a resident Moffitt Cancer Center pathologist to 
determine the histological subtype of the lesions. 
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Figure 32. Kaplan-Meier tumor free survival curves for bitransgenic mice compared to 
monotransgenic or wild type controls. The Log rank test was used for statistical analysis 
to compare bitransgenic mice to either wild type or monotransgenic controls. Both test 
yielded p < 0.0001. (The numbers inside parentheses in graph legend indicate the total 
number of mice in each group) 
 
 
Biochemical analysis confirmed that SHP2E76K expression was no longer detectable 
after Dox withdrawal (Fig. 35A). In the absence of the positive regulatory effects of 
SHP2E76K, pErk1/2, pSrc, and c-Myc all returned to levels comparable to wild type 
controls (Fig. 35B). These results were further supported by IHC staining of lung tissues 
with a pErk1/2 antibody. Strong pErk1/2 staining is detectable in SHP2E76K induced lung 
tumors (Fig. 35C). After Dox withdrawal, pErk1/2 staining intensity was comparable to 
wild type controls (Fig. 35C). 
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Figure 33. MRI pilot study. CCSP-rtTA/tetO-SHP2E76K mice were Dox induced for 9 
months then imaged by the Moffitt Cancer Center small animals imaging core staff. 
Animals with MRI detectable lung tumors were euthanized and dissected to confirm the 
presence of tumors in the area seen in MR images. (n=4) 
 
 
3.4.5 SHP2E76K auto-regulates phosphorylation of its docking protein Gab1 
To determine the mechanisms of SHP2E76K driven lung tumorigenesis we sought to 
identify the binding partners of SHP2E76K in the lungs of CCSP-rtTA/tetO-SHP2E76K 
mice. SHP2E76K immunoprecipitates were obtained from lung tissue of Dox induced 
bitransgenic mice, separated on a 10% SDS polyacrylamide gel, and immunoblotted 
with a PY20 antibody (Fig. 36 A). Gel bands corresponding to phosphorylated tyrosines 
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on immunoblot were analyzed by mass spectrometry. The proteins identified by mass 
spectrometry are listed in Table 4. One of the top candidates was Gab1. Further 
analysis using co-immunoprecipitation confirmed that Gab1 and the SHP2E76K mutant 
associate in the lungs of bitransgenic CCSP-rtTA/tetO-SHP2E76K mice (Fig. 36B).  
 
Figure 34. Dox withdrawal causes lung tumor regression. (A) CCSP-rtTA/tetO-SHP2E76K 
mice were Dox induced for 9 months. A first round of MR imaging confirmed presence 
of tumors in the lungs of bitransgenic animals. Mice were then placed on regular chow 
for a month, and imaged for a second time using similar conditions. (n=6) (B) After the 
second round of MRI analysis, bitransgenic mice were sacrificed and lung tissue 
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collected. H&E slides were prepared by the Moffitt Cancer Center Histology Core and 
evaluated by a pathologist to check for presence of residual lesions.  
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Figure 35. Dox withdrawal abrogates the positive regulatory effects of SHP2E76K in the 
lungs of CCSP-rtTA/tetO-SHP2E76K mice. (A) Lung tissue was collected from CCSP-
rtTA/tetO-SHP2E76K mice following the second round of MRI after 1 month Dox 
withdrawal. Tissue was snap frozen in liquid nitrogen and divided in half to extract both 
RNA and protein. RT-PCR was performed according to manufacturer’s protocol. Flag-
tagged SHP2E76K was immunoprecipitated using Flag antibody and Protein-G agarose 
beads followed by 10% SDS-polyacrylamide gel separation and immunoblot with Flag 
antibody. (B) Lungs were collected from wild type and pre or post Dox induced CCSP-
rtTA/tetO-SHP2E76K mice. Protein extraction was followed by 10% SDS-polyacrylamide 
gel separation and immunoblot with indicated antibodies. (C) Lung slides from pre and 
post induction CCSP-rtTA/tetO-SHP2E76K or wild type mice were stained with pErk1/2 
antibody. (WT - wild type, B - bitransgenic) 
 
 
 
Figure 36. SHP2E76K expression induces Gab1 phosphorylation and Gab1/SHP2 
association in the lungs of CCSP-rtTA/tetO-SHP2E76K mice. (A) Protein was extracted 
from the lungs of CCSP-rtTA/tetO-SHP2E76K mice and immunoprecipitated using Flag 
antibody and Protein-G agarose beads. Immunoblot was performed using PY20 
antibody following 10% SDS-polyacrylamide gel separation. (B) Protein was extracted 
from the lungs of CCSP-rtTA/tetO-SHP2E76K mice and immunoprecipitated using Flag 
antibody and Protein-G agarose beads. Immunoblot was performed using indicated 
antibodies following 10% SDS-polyacrylamide gel separation. (C) Lungs were collected 
from wild type and pre or post Dox induced CCSP-rtTA/tetO-SHP2E76K mice. Protein 
extraction was followed by 10% SDS-polyacrylamide gel separation and immunoblot 
with indicated antibodies. (WT - wild type, B - bitransgenic) 
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Table 4. SHP2E76K bound proteins identified by mass spectrometry.  
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Table 4 continued 
 
Table contains top candidates with a minimum of 3 matching peptides. Protein 
identification by mass spectrometry was performed by the Moffitt Cancer Center 
Proteomics Core. Tryptic peptides from gel slides were analyzed with a nanoflow liquid 
chromatograph coupled to an electrospray ion trap mass spectrometer for tandem mass 
spectrometry peptide sequencing. Five tandem mass spectra were collected in a data-
dependent manner following each survey scan. Sequences were assigned using 
Mascot (www.matrixscience.com) searches against mouse entries. (M.W. - Molecular 
weight is an approximation, not exact value) 
 
Previous work has shown that Gab1/SHP2 association is required for SHP2 
activation and that GOF SHP2 mutants are non-functional if they lack intact SH2 binding 
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domains [33, 34]. These studies indicate that acquisition of a GOF SHP2 mutation is not 
sufficient to induce cellular transformation; recruitment of the PTP to the cell membrane 
by docking proteins is a required step in this process. Since Gab1 is the main docking 
protein of SHP2 and was identified in our mass spec analysis, we decided to focus our 
attention on Gab1. 
Dox induced CCSP-rtTA/tetO-SHP2E76K mice expressed elevated levels of 
phosphorylated Gab1 compared to wild type controls or bitransgenic mice after Dox 
withdrawal (Fig. 36C). To confirm these results, we expressed the SHP2E76K mutant in 
TF-1 and H292 cells, and saw an increase in pGab1 as well as activation of the Src 
family of kinases [60]. These results indicate that the SHP2E76K mutant can promote its 
own activation by regulating the phosphorylation of its own docking protein. 
To determine which protein tyrosine kinase is responsible for SHP2E76K mediated 
Gab1 phosphorylation, we treated H292/SHP2E76K cells with Ruxolitinib, Dasatinib or 
Erlotinib inhibitors which target Jak, SFKs, and EGFR respectively. Ruxolitinib had no 
effect on pGab1 levels, while Dasatinib and Erlotinib significantly reduced Gab1 
phosphorylation [60]. To determine whether Src activity is also required for induction of 
Gab1 phosphorylation by a different GOF SHP2 mutant we treated H661 lung cancer 
cells which express the SHP2N58S mutant with Dasatinib. As described earlier, Src 
inhibition decreased pGab1 levels and caused a dissociation of the Gab1/SHP2 
complex [60]. We further confirmed these results using a siRNA approach. Pan Src 
knock-down using a Src SiRNA also reduced pGab1 levels in H661 cells [60]. To 
identify specifically which SFK is responsible for Gab1 phosphorylation, we used siRNA 
targeting Lyn and Lck. Only Lyn knock-down in H292/SHP2E76K cells decreased pGab1 
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levels, indicating that Lyn is the mediator of SHP2E76K induced Gab1 phosphorylation 
[60]. These results indicate that GOF SHP2 mutants potentially induce Gab1 
phosphorylation through activation of the SFKs.  
To confirm that this mechanism of Gab1 activation is specific to GOF SHP2 mutants, 
we tested the erythroleukemia cell line Hel as a control. Cell transformation and 
aberrant tyrosine phosphorylation events in this cell line are mediated by the GOF 
Jak2V617F mutant. Ruxolitinib but not Dasatinib treatment inhibited Gab1 tyrosine 
phosphorylation in Hel cells (Fig. 37). To verify the specificity of these two inhibitors, we 
confirmed that Ruxolitinib treatment decreased Jak2 phosphorylation but not Src 
phosphorylation, while Dasatinib reduced active Src but not pJak2 in these cells (Fig. 
37).  
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Figure 37. Ruxolitinib and Dasatinib treatment of Hel cells. Hel cells were grown to 
confluence in complete medium then serum starved for 16 hours. Cells were treated 
with indicated concentrations of Dasatinib or Ruxolitinib in complete medium for 24 
hours followed by protein extraction. Immunoblot was performed with indicated 
antibodies following 10% SDS-polyacrylamide gel separation. 
 
 
 
 
3.5 Discussion  
GOF SHP2 mutations are well known leukemic oncogenes but their contribution to 
carcinogenesis is mostly undefined [177, 178]. SHP2E76K is a constitutively active GOF 
SHP2 mutant found in human cancers, including NSCLC. To determine the role of 
SHP2E76K in lung tumorigenesis, we generated a novel Dox inducible CCSP-rtTA/tetO-
SHP2E76K mouse model. SHP2E76K expression promoted Ras/MAPK and Src pathway 
cell signaling by activating the Erk1/2 and Src kinases and increasing c-Myc levels.  
After 6 months of Dox induction, the majority of CCSP-rtTA/tetO-SHP2E76K 
bitransgenic mice displayed atypical adenomatous hyperplastic lesions and 31% 
developed adenomas. At the 9 months time point, 87% of Dox-induced CCSP-
rtTA/tetO-SHP2E76K bitransgenic mice displayed adenomas and adenocarcinomas, 
whereas only 15% of control mice of the same inbred strain developed lung tumors. 
Moreover, the tumors found in control mice were notably smaller compared to those 
found in bitransgenic CCSP-rtTA/tetO-SHP2E76K mice, indicating that SHP2E76K 
expression might trigger earlier tumor onset, faster tumor growth, or both. The fact that 
no control mice developed tumors at the 6 months time point further supports this 
notion. These results demonstrate that the SHP2E76K mutant is a driver of 
  
 
 
92 
carcinogenesis in lung epithelial cells and describe a novel role for SHP2 as a lung 
cancer oncogene. 
The majority of Dox induced CCSP-rtTA/tetO-SHP2E76K bitransgenic mice displayed 
a tumor latency longer than 6 months. A potential explanation for this phenomenon is 
that endogenous wild type SHP2 competes with the SHP2E76K mutant for the same 
docking proteins thus reducing the transforming effect of SHP2E76K. This does not seem 
to be the case in our mice though, since SHP2E76K expression positively regulated cell 
signaling in the lungs of our bitransgenic mice. An alternative mechanism is that 
SHP2E76K expression induces genomic instability leading to the acquisition of one or 
more secondary mutations that promote the expansion of proliferative lesions. The 
validity of this multigenic hypothesis is supported by the fact that CCSP-rtTA/tetO-Myc 
mice display a long tumor latency of 300 days. The lung tumors observed in these mice 
acquire a secondary Kras mutation. Moreover, tumor development is also accelerated in 
mice by exposure to a chemical carcinogen or breeding onto a high Mcl1 background 
[174]. Consistent with our previous finding that SHP2 upregulates c-Myc in lung 
carcinoma cells in culture, we observed increased c-Myc levels in the lungs of Dox-
induced CCSP-rtTA/tetO-SHP2E76K bitransgenic mice. Myc plays an important role in 
cell proliferation and might significantly contribute to SHP2E76K mediated tumorigenesis  
[153]. 
If the multigenic hypothesis of SHP2E76K mediated lung tumorigenesis is correct, 
then tumor growth and survival should be independent of SHP2E76K expression. We 
investigated this concept by taking advantage of the reversible feature of our Dox 
inducible transgenic mouse model. We used an MRI approach to detect lung tumors in 
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Dox induced bitransgenic mice. We then withdrew doxycycline for a month and 
performed a second round of MRI. The MR images and follow-up histological evaluation 
revealed that lung tumors not only stopped growing, but regressed in the absence of 
SHP2E76K expression. These results indicate that tumor maintenance in Dox induced 
CCSP-rtTA/tetO-SHP2E76K mice is dependent on sustained SHP2E76K expression and 
that SHP2E76K is the main driver of lung carcinogenesis in this bitransgenic mouse 
model.  
Previous work has shown that augmentation of PTP activity is not sufficient to 
induce cellular transformation. SHP2 must first be recruited to the cell membrane and 
associate with docking proteins to function properly [33, 179]. This association is 
mediated by phosphorylation of the SHP2 binding sites on the docking proteins. An 
important question is since the GOF SHP2E76K mutant is clearly functional in the lungs 
of our bitransgenic mice, how is phosphorylation of the docking protein maintained in 
these animals? A potential answer is that GOF SHP2 mutants can positively regulate 
the phosphorylation of their own docking protein. This notion is supported by  previous 
research in our lab showing that SHP2 knock-down in H292 cells impairs basal and 
EGF stimulated tyrosine phosphorylation of the Gab1 SHP2 binding sites Y627 and 
Y659 [153].  
Since Gab1 is the main SHP2 docking protein and was identified as a top candidate 
in our mass spectrometry experiment, we started by evaluating the tyrosine 
phosphorylation of the SHP2 binding sites. We identified higher levels of pGab1 in the 
lungs of our bitransgenic mice, TF-1/SHP2E76K cells, and H292/SHP2E76K cells. These 
data indicate that SHP2E76K does indeed autoregulate the tyrosine phosphorylation of 
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Gab1 and its binding to this docking protein. Additional experiments using PTK 
inhibitors revealed that EGFR or SFKs inhibition by Erlotinib or Dasatinib reduces 
pGab1 levels in H292/SHP2E76K and H661 cells. This effect can be replicated using 
SFKs siRNAs in these cells. More specifically, Lyn knock-down had the strongest 
impact on Gab1 phosphorylation in H661 cells. Since SHP2 knock-down has a negative 
effect on SFKs activation and SHP2E76K expression increases pSrc levels in cell culture 
models and the lungs of CCSP-rtTA/tetO-SHPE76K, our results suggests that the 
SHP2E76K mutant promotes its own activation by activating the SFKs and triggering a 
positive feed-forward loop system [153]. 
 
Figure 38. SHP2E76K mechanism of action in CCSP-rtTA/tetO-SHP2E76K mice. EGFR 
phosphorylates Gab1 and recruits SHP2E76K which induces activation of the Lyn kinase. 
Lyn then phosphorylates Gab1, initiating a positive feedback loop. 
 
In conclusion, we have described a novel role for the GOF SHP2E76K mutation as an 
oncogene in lung carcinoma by generating a Dox inducible transgenic mouse model 
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that exhibits a disease phenotype similar to NSCLC patients. We also described a new 
mechanism of GOF SHP2 mutant activation through a positive feedback loop involving 
the docking protein Gab1 and the SFKs.  
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Chapter 4: Concluding remarks 
 
The protein tyrosine phosphatase SHP2 plays an important role in normal cellular 
function. This protein is expressed ubiquitously and positively regulates multiple 
signaling pathways, including the Ras/MAPK and Src cell signaling pathways resulting 
in increased cell proliferation, survival, and motility [34, 36, 47, 180]. Because of its 
extensive function, SHP2 also plays a prominent role in cancer [58]. GOF SHP2 
mutations are known leukemic oncogenes, and SHP2 acts as a cancer essential gene 
through over-expression or amplification in several types of malignancies [55, 59, 177]. 
Since the role of SHP2 in lung cancer is incompletely defined, the studies described in 
this dissertation aim to elucidate the oncogenic potential of a GOF SHP2 mutant in vitro 
and in vivo and to figure out whether SHP2 is a synthetic lethal gene in GOF EGFR 
mutant dependent lung cancer. 
 
4.1 Chapter 2 summary and conclusions  
In the second chapter of this dissertation, we aimed to establish SHP2 as a synthetic 
lethal gene in GOF EGFR mutant dependent lung cancer. To achieve this goal, we 
performed in vitro experiments and generated a novel Dox inducible transgenic mouse 
model expressing the dominant negative SHP2CSDA mutant under the control of the 
CCSP promoter to direct expression to lung epithelial cells. 
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Using two GOF EGFR mutant dependent lung cancer cell lines, we showed that 
interfering with normal SHP2 function through shRNA knock-down, siRNA knock-down, 
PTP catalytic domain inhibition, or expression of the dominant negative SHP2CSDA 
mutant reduced cell proliferation and Ras/MAPK cell signaling pathway activity. These 
results indicate that targeting SHP2 in vitro can have a significant effect on GOF EGFR 
mediated cell signaling and proliferation.   
Based on the previous results, we generated a Dox inducible transgenic mouse 
model and bred bitransgenic CCSP-rtTA/tetO-EGFRL858R mice and tritransgenic CCSP-
rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice. Expression of the SHP2CSDA mutant in the 
lungs of tritransgenic mice decreased EGFRL858R mediated Ras/MAPK and Src cell 
signaling pathway activation, leading to delayed tumor onset and reduced tumor 
burden. 
To elucidate the mechanism of action of the SHP2CSDA mutant in the lungs of 
tritransgenic mice, we performed a mass spectrometry analysis and identified Gab1 as 
one of the main binding partners of SHP2CSDA. Further experiments in vitro revealed that 
GOF EGFR mutants phosphorylated Gab1 on its SHP2 binding site, and that GOF 
EGFR mutant inhibition caused a dissociation of the Gab1/SHP2 complex which might 
be responsible for the decreased levels of pErk1/2, pSrc, and cell proliferation. These 
results were further supported by showing that EGFRL858R expression in the lungs of 
bitransgenic mice increased pGab1 levels and Gab1/SHP2 association, while SHP2CSDA 
expression in tritransgenic mice countered these effects and fully disrupted Gab1/SHP2 
complex formation. 
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SHP2 is required to promote wild type EGFR mediated cell signaling [34, 150, 151]. 
In this project we demonstrated that SHP2 is also required to transduce GOF EGFR 
mutant cell signaling and that targeting SHP2 has significant effects on GOF EGFR 
mutant mediated lung tumorigenesis. Our work and others describes a novel role for 
SHP2 as a synthetic lethal gene in GOF EGFR mutant dependent lung cancer [144]. In 
a time where alternative options to EGFR tyrosine kinase inhibitors are urgently needed, 
our results establish the potential of SHP2 as a novel therapeutic target for drug 
development to treat GOF EGFR mutant dependent lung cancer patients. 
 
4.2 Chapter 3 summary and conclusions 
In the third chapter of this dissertation we determined whether the GOF SHP2E76K 
mutant can induce tumor formation in the lungs of bitransgenic CCSP-rtTA/tetO-
SHP2E76K mice. We generated a novel doxycycline inducible transgenic mouse model 
using the tet-on approach to induce transgene expression and used a recombinant 
Clara cell secretory protein promoter to direct expression of the GOF SHP2E76K mutant 
to lung epithelial cells.  
SHP2E76K expression in the lungs of bitransgenic mice following one month of Dox 
induction significantly increased levels of pErk1/2, pSrc, Myc and Mdm2. Myc is a 
downstream target of SHP2 and an important driver of cell proliferation [153]. Elevated 
Myc levels combined with the increased Ras/MAPK and Src cell signaling pathways 
activation are most likely responsible for the appearance of atypical adenomatous 
hyperplastic lesions and adenomas after 6 months of Dox induction. At the nine months 
time point, a significant majority of bitransgenic CCSP-rtTA/tetO-SHP2E76K mice 
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developed adenomas compared to wild type or monotransgenic controls. These results 
establish the GOF SHP2E76K mutant as a novel driver oncogene of lung tumorigenesis 
in our mouse model. 
Since our bitransgenic mice displayed such a long latency to tumor development, we 
suspected that the animals had acquired secondary mutations responsible for tumor 
formation. Despite the presence of these additional mutations, we hypothesize that 
SHP2E76K remained the main driver of tumorigenesis and that sustained transgene 
expression was required for tumor maintenance. To test this hypothesis, we took 
advantage of the reversible feature of our transgenic mouse model. We used MRI to 
check for the presence of lung tumors in bitransgenic mice after nine months of Dox 
induction then withdrew doxycycline for a month. A second round of MRI revealed that 
the lung tumors had either regressed or completely disappeared indicating that while it 
is highly likely that our bitransgenic mice acquired secondary mutations, the main driver 
of tumorigenesis remained the GOF SHP2E76K mutant. 
In an effort to determine the mechanism of SHP2E76K driven tumor formation in the 
lungs of our bitransgenic CCSP-rtTA/tetO-SHP2E76K mice we performed a mass 
spectrometry analysis to identify the binding partners of the SHP2E76K mutant. The 
docking protein Gab1 was identified as one of the top candidates. Previous work has 
shown that solely enhancing the catalytic activity of SHP2 through acquisition of a GOF 
mutation is not sufficient to increase cell signaling, the GOF SHP2 mutant must be 
recruited to the cell membrane to properly function [33, 34]. Gab1 is one of the main 
docking proteins of SHP2 and association between the two proteins leads to SHP2 
relocation to the cell membrane and activation [35]. Interestingly, we demonstrated that 
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GOF SHP2 mutants can increase the phosphorylation level of Gab1 both in vitro and in 
vivo, indicating that mutant SHP2 can auto-regulate the phosphorylation of its own 
docking protein. Further work revealed that this mechanism is most likely mediated 
through recruitment of the SFKs and is specific to GOF SHP2 mutants. 
GOF SHP2 mutants are well known leukemic oncogenes, but their contribution to 
carcinogenesis in solid tumors is mostly unknown. According to the COSMIC database, 
GOF SHP2 mutations, including the SHP2E76K mutation used in our transgenic mouse 
model, have been identified in about two percent of lung cancer cases, but their 
potential contribution to tumorigenesis is unclear. Due to the high prevalence of lung 
cancer, even two percent of cases accounts for a large number of patients. In this 
project, we describe for the first time that a GOF SHP2 mutant can act as an oncogene 
in lung epithelial cells, meaning that the GOF SHP2 mutations identified in lung cancer 
patients could potentially be contributing or even driving carcinogenesis. Our results 
establish SHP2 as a potential novel lung cancer oncogene and highlight a need to 
further investigate the role of SHP2 in lung cancer to determine its potential as a 
therapeutic target for drug development. 
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